Clinical site	Patient ID	Sex	Age at diagnosis	Diagnosis or Relapse	Date of sampling	Date of relapse	Relapse	Time to relapse	OS days	OS code	EFS days	EFS code	DFS days	DFS code	RFS code	Karyotype	Mutations (sequencing in Paris)	Genetic abnormality at initial diagnostic (clinically validated)	Risk category based on 2022 ELN AML risk classification by genetics at initial diagnosis	Risk category based on 2017 ELN AML risk classification by genetics at initial diagnosis	Cytogenetic risk (MRC)	Differenciation	MRD	Category of AML	Diagnostic qualifiers based on 2022 ELN AML Recommandations / 2022 International Consensus Classification	FAB	Hemoglobin at diagnosis	Platelets at diagnosis	Leucocytes at diagnosis	Blasts in blood at diagnosis	Blasts in BM at diagnosis	Ferritine	Transferrine	Fer	Capacit?? total de fixation	Coefficient de saturaion transferrine	vit D	vit C	Bilirubin levels	Bilirubin levels	Bilirubin levels	Creatinemia	Glucose	Total cholesterol	HDL-cholesterol level	LDL-cholesterol level	Triglycerids level	LDH	Treatment	First day of treatment	Allogeneic Hematopoietic Cell Transplantation	Date of HCT	Response based on 2022 ELN AML Recommandations	Date of CR evaluation	Death	Date of death	Exposure to smoking	Exposure to alcohol	Professional exposure	Exposure to benzene	Exposure to cancer chemotherapy	Exposure to ionizing radiations	Exposure to formaldehyde	Weight	Height	BMI	Diabete	Diabete	Atherosclerosis	HTA	Dyslipidemia	Cancer	Cancer	Chronic auto-immune disease or chronic inflamatory disease	Chronic auto-immune disease or chronic inflamatory disease	Osteoporosis	Genetic metabolic carbohydrate disorder	Genetic metabolic lipid disorder	Genetic metabolic mitochondria disorder	RNAseq	Affymetrix	mtDNAseq	Mitoscore 	HOxPHOS score	SRC score #75	LSC score	Engrafters NE/LE/HE	Injected PDX yes/no	Response to araC in vivo	Serum (y/n)	Basal OCR Seahorse	ATP Turnover Seahorse	Max OCR Seahorse	SRC absolu Seaborse	Non-mt Seahorse	Proton Leak Seahorse	Basal ECAR Seahorse	Max ECAR Seahorse	OCR basal / ECAR basal	OCR basal / ECAR max	OCR max / ECAR basal	OCR max / ECAR max	Scenith	Mito FAO - Mito AAO dependency	Mito capacity	MTG	TMRE	Mito Fitnees	Reponse to FCCP	mtCa2+ RHOD2	mtIron RPA
TUH	1	1	0	2				#REF!		0						ND	nd									  					0.52										0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	2	1	81	1	05/14/14			#REF!		0						46,XY,t(4;15)(q27;q14)?c<19>/47,idem,+8<1>	nd			2						4					17% (+47%promonocytes)										0														0											#DIV/0!															n						LE	Yes		n																		#DIV/0!			
TUH	3	2	63	1	05/23/14			#REF!		0						46,XX,inv(4)(p14q24)<6>/46,XX,der(21)t(1;21)(q21;q22)<1>/47,XX,der(21)(1;21),+20<3>/46,XX,der(3)t(1;3)(q21;q2?6)<1>/46,XX,der(16)t(1;16)(q21;p13)<1>/46,XX,der(16)t(1;16)(q21;q24)<1>/46,XX<10>	nd			2						5					89% (+2%promono)										0														0											#DIV/0!															n						NE	Yes		n																		#DIV/0!			
TUH	4	2	53	1	09/04/14			#REF!		0						46,XX<20>	nd			2						1					0.96										0														0											#DIV/0!															n						LE	Yes		n																		#DIV/0!			
TUH	5	1	58	1	09/12/14			#REF!		1						46,XY<20>	nd			2						2					0.2										0														1	11/02/14										#DIV/0!															n						NE	Yes		n																		#DIV/0!			
TUH	6	2	78.6164383561644	1	10/06/14				27	1	27	1				N	NPM1 ; STAG2	k = N ; m = NPM1, STAG2	3	2	2	CMP		AML with myelodysplasia-related gene mutations (STAG2) or AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	9.1	18	247.42	95	94	499.8	nd	nd	nd	nd	nd	nd	20.6	12.3	8.3	67	6	3.78	nd	nd	3.1	990	BSC		0		0	ND	1	11/02/14	no	no	aidait son ??poux dans la ma??onnerie	no	no	no	no	nd	nd	nd	no	no	no	yes	yes	no	no	no	no	no	no	no	no	 1 - 2 - 3	y			High			HE	Yes	High	n	nd	nd	nd	nd	nd	nd	nd	nd					Yes			73563.586	1205907.5	16.3927231606137	11	18488	
TUH	7	1	52.1808219178082	1	10/07/14				779	0	779	0	731	0	0	inv(16)	IKZF1 ; KIT	k = inv16 tri22 ; m = KIT, IKZF1	1	1	1	GMP		AML with recurrent genetic abnormalities (AML with inv(16))		4	4.4	74	104.3	23	77	2326.4	1.3	23	nd	68	nd	nd	27.7	20	7.7	68	5.7	2.9	nd	nd	1.3	146	CTI	08/10/14			1	11/24/14	0	11/24/16	yes, undetailed	no	m??canicien	no	no	no	no	80	1.8	24.6913580246914	no	no	yes	no	no	no	no	no	no	no	no	no	no	1	y			High	High		HE	Yes	Low	n	56.54	38.93	219.87	163.33	10.07	7.53	11.95	22.6	4.73138075313808	2.50176991150442	18.3991631799163	9.7287610619469	Yes					#DIV/0!			
TUH	8	1	63.3013698630137	1	11/26/14				2758	0	2758	0	2724	0	0	MLL-XXX t(11;17)	TET2 ; KRAS ; NF1	k = MLL-XXX t(11;17) ; m = TET2 ; KRAS ; NF1 	3	3	3	GPMP		AML with recurrent genetic abnormalities (APL with other RARA rearrangements = APL with t(11;17))		5	11.1	85	69.53	4	93	424.9	nd	nd	nd	nd	nd	nd	8.8	nd	nd	203	6.5	1.87	nd	nd	1.1	402	CTI	28/11/2014	1	04/09/15	1	12/30/14	0	06/15/22	no	no	chauffeur routier et militaire	no	no	no	no	85	nd	nd	no	no	no	yes	no	no	no	no	no	no	no	no	no	 1 - 2	y			Low			HE	Yes	High	n																		#DIV/0!			
TUH	9	1	66.627397260274	1	12/09/14	02/20/20		1899	2129	1	1899	1	1850	1	1	tri8	nd	k = tri8 ; m = 0	2	2	2	GPMP		AML with myelodysplasia-related cytogenetic abnormalities (tri8)		5	10.2	175	95.25	3	58	855.3	nd	nd	nd	nd	nd	nd	12.2	nd	nd	58	5.3	3.91	nd	nd	0.83	134	CTI	12/12/14	0		1	01/27/15	1	10/07/20	30 PA	no	chef d'entreprise de construction	no	no	no	no	67	1.62	25.5296448712087	no	no	no	yes	no	no	no	no	no	no	no	no	no		n						HE	Yes	High	n																		#DIV/0!			
TUH	10	2	64.4	1	01/12/15	04/23/15			176	1	101	1	50	1	1	N	NPM1 ; TET2 ; DNMT3A	k = N ; m = NPM1 ; TET2 ; DNMT3A	1	1	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)		5	8.7	81	306.78	58	85	2434	nd	nd	nd	nd	nd	nd	2.8	nd	nd	55	5.8	4.99	nd	nd	2.71	680	CTI	15/01/2015	0		1	03/04/15	1	07/07/15	no	no	aide soignante	no	no	no	no	58	1.5	25.7777777777778	no	no	no	yes	no	no	no	no	no	no	no	no	no	 1 - 2	y			High	Low		HE	Yes	Low	n	35.51	20.13	107.82	72.31	8.76	6.63	11.04	15.25	3.21648550724638	2.32852459016393	9.76630434782609	7.07016393442623	Yes					#DIV/0!			
TUH	11	2	22.2438356164384	1	01/22/15	06/01/15		130	324	1	130	1	96	1	1	N	NPM1 ; DNMT3A	k = N ; m = NPM1 ; DNMT3A	1	2	2	CMP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	12.4	41	161.16	93	92	412.5	nd	nd	nd	nd	nd	nd	11.7	nd	nd	60	9.5	5.35	nd	nd	2.28	743	CTI	23/01/2015	0		1	02/25/15	1	12/12/15	no	no	??tudiante en master de biologie v??g??tale	no	no	no	no	80	1.58	32.0461464508893	no	no	no	no	no	no	no	no	no	no	no	no	no	1	y			High			HE	Yes	High	n																		#DIV/0!			
TUH	12	1	59	1	01/30/15			-42034		0						58-62<3n>,XY,der(1)t(1;8)(q24;q21),der(1)(?::7q35->7q11::1p32 ->1qter),add(2)(p11),-3,-4,add(6)(p21),der(7)t(2;7)(p21;q35), der(8)t(1;8)(p31;q21),-9,-10,-11,+12,add(12)(q11)x2,add(13) (p11),-14,-16,-17,-18,dup(18)(q11q22),-20,+add(21)(q22),+4mar <cp4>/59-63,sl,-add(6)(p21),+6,del(8)(q21q23)<cp10>/46,XY<6>	nd			3						5					80										0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	13	2	54	1	02/03/15	NA		#VALUE!		0						N	NPM1 ; TET2 ; DNMT3A	k = N ; m = FLT3-ITD ; NPM1 ; DNMT3A	2	2				AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	10.8	16	103	80	89	6065	nd	nd	nd	nd	nd	nd	26.7	16	10.7	62	6.7	3.61	nd	nd	2.12	1618	CTI	02/04/15					0		no	no	assistante maternelle	no	no	no	no	89.4	nd	nd	no	no	no	no	no	no	no	no	no	no	no	no	no	1	y			High			HE	Yes	High	n																		#DIV/0!			
TUH	14	2	61.0684931506849	1	02/12/15	11/03/15		264	421	1	264	1	210	1	1	N	nd	k = N ; m = NPM1 ; TET2 ; CEBPA	1	2	2	GP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	8.3	24	304.02	92.2	92	2030	nd	nd	nd	nd	nd	nd	9	nd	nd	53	8.4	nd	nd	nd	2.45	1281	CTI	12/02/15	0		1	04/07/15	1	04/08/16	nd	nd	nd	nd	nd	nd	nd	59.7	1.65	21.9283746556474	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd		n						NE	Yes		n																		#DIV/0!			
TUH	15	2	73	1	02/13/15			-42048	278	1						46,XX,del(5)(p15p13),add(6)(q2?5),add(14)(q3?2)<17>/46,XX<4>	nd			2						1					93										0														1	11/18/15										#DIV/0!															n						NE	Yes		n																		#DIV/0!			
TUH	16	1	73	1	03/12/15	09/10/15		182	135	1						N	FLT3-TKD ; NPM1 ; WT1	k = N ; m = NPM1	1	2				AML with recurrent genetic abnormalities (AML wth mutated NPM1)	Therapy-related (prior chemotherapy ; radiotherapy)	1	10.5	27	78	87	85	2249	nd	nd	nd	nd	nd	nd	5.8	nd	nd	86	3.9	4.37	nd	nd	0.97	540	CTI	03/12/15					1	07/25/15	no	no	??lectricien artisan	no	yes	yes	no	72	nd	nd	yes	DT2	no	no	no	yes	adenoK rectal	no	no	no	no	no	no	1	y			Low			HE	Yes	Low	n																82982.984	812897.875	9.79595859073952	12	17472	
TUH	17	2	68	2	03/17/15	02/23/15		-22		1						t(9;11) AF9-MLL	nd	k = t(9;11) AF9-MLL ; m = 0	2	2				AML with recurrent genetic abnormalities (AML with t(9;11))		2	9	10	25.6	nd	67	875.9	nd	nd	nd	nd	nd	nd	2.3	nd	nd	72	17.6	4.11	nd	nd	3.46	506	CTI	03/17/15					1		no	no	nd	no	no	no	no	nd	nd	nd	no	no	no	yes	no	yes	fibrome ut??rin	no	no	no	no	no	no	1	y			High			HE	Yes	High	n																		#DIV/0!			
TUH	18	1	54.6602739726027	1	03/16/15				2088	0	2088	0	1981	0	0	inv(16)	nd	k = inv16 ; m = FLT3-TKD	1	1	1	GMP		AML with recurrent genetic abnormalities (AML with inv(16))		4	12.7	78	71.24	44	na	2285	nd	nd	nd	nd	nd	nd	21.8	13.1	8.7	51	7.3	3.4	nd	nd	1.35	530	CTI	19/03/2015			1	07/01/15	0	12/02/20	15 PA	0,25 mL of wine everyday at leats, and aperitives somedays	??ducateur et maire d'Ibos	no	no	no	no	88	1.83	26.2772850786825	no	no	no	no	no	no	no	no	no	no	no	no	no		y			High			HE	Yes	High	n																		#DIV/0!			
TUH	19	2	57.8739726027397	1	05/11/15				28	1	28	1				N	RUNX1 ; WT1	k = N ; m = RUNX1 ; WT1 ; FLT3-ITD	2 or 3 ??	2	2	GMP		AML with myelodysplasia-related gene mutations (RUNX1)		4	7.6	49	219.09	32	46	2250	nd	nd	nd	nd	nd	nd	22.6	11.9	10.7	69	8.7	nd	nd	nd	1.76	3096	CTI	14/05/2015	0		0	ND	1	06/08/15	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	1	n			High			HE	Yes	Low	n																		#DIV/0!			
TUH	20	2	35.9780821917808	1	06/03/15	08/09/18		1163	1625	1	1163	1	1109	1	1	N	RUNX1 ; WT1	k = N ; m = RUNX1 ; WT1 ; FLT3-ITD	2 or 3 ??	2	2	CMP		AML with myelodysplasia-related gene mutations (RUNX1)		4	9.4	51	207.55	40	79	nd	nd	nd	nd	nd	nd	nd	6.2	nd	nd	65	7.2	3.57	nd	nd	2.47	130	CTI	04/06/15	1	11/19/15	1	07/27/15	1	11/14/19	no	no	dirige une entreprise de parquet	no	no	no	no	72	nd	nd	no	no	no	no	no	no	no	no	no	no	no	no	no	  1 - 2	n			High			HE	Yes	High	n																		#DIV/0!			
TUH	21	2	54.9232876712329	1	06/09/15	05/12/16		338	2382	0	338	1	296	1	1	N	NPM1	k = N ; m = NMP1 ; FLT3-ITD	2	2	2	CMP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		5	7.5	48	77.39	95	94	593.3	nd	nd	nd	nd	nd	nd	18.9	10	8.9	50	6.1	nd	nd	nd	0.7	1453	CTI	17/06/2015	1	09/13/16	1	07/21/15	0	12/16/21	no	no	h??tesse de caisse ?  intermarch??	no	no	no	no	75.9	1.62	28.9208962048468	no	no	no	no	no	no	no	no	no	no	no	no	no	1	n			Low			HE	Yes	High	n																		#DIV/0!			
TUH	22	2	36.5616438356164	1	02/05/15				373	1	77	1				NUP98 t(X;11)	DNMT3A	k = NUP98 t(X;11) ; m = DNMT3A	3 ??	2	2	GMP		AML not otherwise specified ?? (AML with t(X;11))		4	6.1	73	46.06	13	45	495.6	nd	nd	nd	nd	8	nd	5	nd	nd	58	5.1	4.34	nd	nd	1.24	733	CTI	13/02/2015	0		0	04/23/15	1	02/13/16	< 5 PA	no	no	no	no	no	no	65	1.6	25.390625	no	no	no	no	no	no	no	yes	bronchites ?  r??p??tition	no	no	no	no	 1 - 2	n			High			HE	Yes	High	n																		#DIV/0!			
TUH	23	2	66	2	06/23/15	NA		#VALUE!		1	#VALUE!	1	#VALUE!	1	1	N	NPM1 ; TET2 ; DNMT3A	k = N ; m = NPM1 ; TET2 ; DNMT3A	1	1	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)		5	8.7	81	306.78	58	85	2434	nd	nd	nd	nd	nd	nd	2.8	nd	nd	55	5.8	4.99	nd	nd	2.71	680	CTI	15/01/2015	0		1	03/04/15	1	07/07/15	no	no	aide soignante	no	no	no	no	58	1.5	25.7777777777778	no	no	no	yes	no	no	no	no	no	no	no	no	no	1	n			High			HE	Yes	High	n																		#DIV/0!			
TUH	24	1	75	1	09/08/15			-42255		0						46,XY<20>	nd			2						5					43										0														0											#DIV/0!															n						LE	Yes		n																		#DIV/0!			
TUH	25	1	76	1	09/08/15			-42255		0						46,XY<20>	nd			2						5					52										0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	26	1	52.9890410958904	1	10/21/15	08/22/16		306	377	1	306	1	273	1	1	N	nd	k = N ; m = FLT3-ITD ; NPM1 ; DNMT3A	2	2	2	MP3		AML with recurrent genetic abnormalities (AML with mutated NPM1)		5	10.9	21	56.44	18	77	1718	nd	nd	nd	nd	nd	nd	6.4	nd	nd	141	5.6	2.72	nd	nd	2.01	488	CTI	22/10/2015	1	04/07/16	1	11/23/15	1	11/01/16	40 PA	occasionally	gendarme ; agent de s??curit?? la nuit	no	no	no	no	83	nd	nd	no	no	no	yes	no	no	no	no	no	no	no	no	no		n				Low		LE	Yes		n	25	8.13811133	92.57861	67.7085761	11.1438398	5.58808275	17.18	23.67	1.45518044237485	1.05618926911703	5.38874330616997	3.91122137727081				18513.763	23587.978	1.27407799268036	6	6433	
TUH	27	1	77	1	10/22/15			-42299	342	1						46,XY,-7,+mar<5>/46,XY<11>	DNMT31 ; ASXL1 ; SRSF2			3						2					39										0														1	09/28/16										#DIV/0!															n						LE	Yes		n																98701.578	793756.313	8.04198199343885	11	40482	
TUH	28	2	79	1	10/29/15	02/01/16		95		1						t(1;16) ; inv3	FLT3-TKD ; TET2 ; WT1	k = t(1;16) ; inv3 ; m = 0	3	3				AML with recurrent genetic abnormalities (AML with inv3)		1	13.3	54	202.9	96	94	355.2	nd	nd	nd	nd	nd	nd	6.7	nd	nd	63	6.3	4.12	nd	nd	1.67	1804	CTI	10/29/15					1		no	no	enseignante	no	no	no	no	90	nd	nd	no	no	no	yes	no	yes	fibrome ut??rin	no	no	no	no	no	no	1	n			High	High		HE	Yes	High	n	17.35	5.85	107.8	90.45	7.54	3.96	7.09	12.66	2.44710860366714	1.37045813586098	15.2045133991537	8.51500789889415	Yes					#DIV/0!			
TUH	29	2	65	1	10/28/15	11/16/16		385	910	1	385	1	344	1	1	N	nd	k = N ; m = NPM1 ; FLT3-ITD	2	2	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	9.7	22	40.65	80.2	86	382.5	2.6	14.4	65	22.2	4.8	nd	3.7	nd	nd	56	6.4	4.95	nd	nd	0.86	824	CTI	31/10/2015	1	03/14/17	1	12/08/15	1	04/25/18	no	no	nd	no	no	no	no	54	1.68	19.1326530612245	no	no	no	no	no	yes	fibroad??nome sein G ; kyste dermo??de ovaire G ; k??rato-acanthome	yes	spondylarthrite ankylosante ; rectocolite h??morragique	no	no	no	no		n						LE	Yes		n																		#DIV/0!			
TUH	30	2	61.7917808219178	2	11/03/15				157	1	112	1				N	NPM1 ; TET2 ; CEBPA	k = N ; m = NPM1 ; TET2 ; CEBPA	1	2	2	GP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	9.2	43	146.52	70	81	2030	nd	nd	nd	nd	nd	nd	9	nd	nd	53	8.4	nd	nd	nd	2.45	1281	Autre	04/11/15	0		0	02/23/16	1	04/08/16	nd	nd	nd	nd	nd	nd	nd	59.7	1.65	21.9283746556474	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	1	n			High			HE	Yes	High	n													Yes					#DIV/0!			
TUH	31	1	63.3890410958904	1	11/13/15	09/26/16		318	1476	1	318	1	285	1	1	N	FLT3-TKD ; NPM1 ; TET2	k = N ; m = FLT3 TKD ; NPM1 ; TET2	1	2	2	GP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	11.8	55	76.83	94	93	652	nd	nd	nd	nd	nd	nd	3.3	nd	nd	89	6.8	nd	nd	nd	nd	530	CTI	14/11/2015	1	02/21/17	1	12/16/15	1	11/28/19	nd	nd	nd	nd	nd	nd	nd	70	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	3	n			High			HE	Yes	High	n	nd	nd	nd	nd	nd	nd	nd	nd					Yes					#DIV/0!			
TUH	32	1	32.5890410958904	1	12/02/15	03/31/16		120	199	1	120	1	80	1	1	N	NPM1 ; DNMT3A ; NRAS	k = N ; m = NPM1 ; DNMT3A ; FLT3-ITD	2	2	2	GPMP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		4	5.9	86	97.08	66	72	917.1	nd	nd	nd	nd	nd	nd	4	nd	nd	82	7.3	nd	nd	nd	1.14	942	CTI	03/12/15	1	06/09/16	1	01/11/16	1	06/18/16	no	no	commercial	no	no	no	no	79	1.85	23.0825420014609	no	no	no	no	no	no	no	no	no	no	no	no	no	1	y			High			HE	Yes	Low	n																		#DIV/0!			
TUH	33	2	50.5178082191781	1	01/05/16	06/13/16		160	345	1	160	1	81	1	1	N	0	k = N ; m = FLT3-ITD ; NPM1	2	2	2	CMP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	6.6	432	114	82	86	1366.6	nd	nd	nd	nd	nd	nd	20.4	4	16.4	43	5	4.6	nd	nd	0.6	955	CTI	06/01/16	1	10/12/16	1	03/24/16	1	12/15/16	15 PA	no	travaille ?  la mairie de toulouse	no	no	no	no	57.4	nd	nd	no	no	no	no	no	no	no	no	no	no	no	no	no	1	n			Low			HE masse	Yes	Low	n																		#DIV/0!			
TUH	34	2	54.3452054794521	1	01/16/16				2082	0	2082	0	2034	0	0	N	nd	k = N ; m = FLT3-ITD ; NPM1	2	0	2	GP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	10.2	75	29.11	72	92								10.3	nd	nd	51	6,0 ; Hba1C = 10,1%	5.18	nd	nd	2.86	459	CTI	20/01/2016			1	03/04/16	0	09/28/21	2-3 cigarets per day for 40 years	no	agent de nettoyage	no	no	no	no	118	nd	nd	yes	DT2, uncontrolled	no	yes	no	no	no	no	no	no	no	no	no		n							No		n																121306.055	761699	6.27915069861929	6		
TUH	35	2	55.986301369863	1	07/13/15	01/28/16		199	459	1	199	1	143	1	1	N	NPM1 ; DNMT3A ; SH2B3	k = N ; m = NPM1 ; FLT3-ITD ; SH2B3	2	2	2	MP2		AML with recurrent genetic abnomalities (AML with mutated NPM1)		4	13	104	9.1	14	70	863.7	nd	nd	nd	nd	nd	nd	3.4	nd	nd	90	6.9	5.19	nd	nd	4.44	172	CTI	28/07/2015	1	12/15/15	1	09/07/15	1	10/14/16	18 PA	no	commer??ante, tient des chambres d'h??te	no	no	no	no	72	1.62	27.4348422496571	no	no	no	no	no	no	no	yes	probable BPCO	no	no	no	no	1	n			Low	Low		HE	Yes	High	n	54.63	36.91	40.16	26.51	3.26	4.53	4.6	6.85	11.8760869565217	7.97518248175183	8.7304347826087	5.86277372262774	Yes					#DIV/0!			
TUH	36	2	57	2	07/13/15			-42198		1						? 46,XX<20>	nd			0						4															0														1											#DIV/0!															n							No		n																		#DIV/0!			
TUH	37	2	62		02/11/16			-42411		0							nd			0																					0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	38	2	75.5643835616438	2	09/28/17	02/11/20		866	1059	1	866	1	728	1	1	tri8	nd	k = tri8 ; m = FLT3-ITD	2	0	2	CMP		AML with myelodysplasia-related cytogenetic abnormalities (AML with +8)		R	10.7	27	0.77	12	80								9.9	nd	nd	65	6.7	5.4	nd	nd	0.8	453	Autre	24/10/2017	0		1	02/13/18	1	08/22/20	no	no	professeure des ??coles	no	no	no	no	53	1.56	21.7784352399737	no	no	no	no	no	no	no	no	no	no	no	no	no		n							No		n																434357.507	2601847.695	5.99010642861987	13		
TUH	39	2	54.7643835616438	1	02/29/16				2017	0	2017	0	1973	0	0	N	nd	k = N ; m = nd		0	2	GP				2	11.5	104	28.55	55	na										0								CTI	29/02/2016			1	04/13/16	0	09/07/21										#DIV/0!															n							No		n																		#DIV/0!			
TUH	40	1	32.9178082191781	2	03/31/16				79	1	43	1				N	NPM1 ; DNMT3A	k = N ; m = NPM1 ; DNMT3A ; FLT3-ITD	2	2	2	GPMP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		4	8.9	71	98.32	89	89	917.1	nd	nd	nd	nd	nd	nd	4	nd	nd	82	7.3	nd	nd	nd	1.14	942	Autre	07/04/16	0		0	05/13/16	1	06/18/16	no	no	commercial	no	no	no	no	79	1.85	23.0825420014609	no	no	no	no	no	no	no	no	no	no	no	no	no	 1 - 2	n			High ?			HE	Yes	Low	n																		#DIV/0!			
TUH	41	1	54		03/24/16			-42453	22	1						? 46,XY,INV(3)(Q21Q26),T(8;22)(P12;Q11)<16>	nd			0						ND															0														1	04/15/16										#DIV/0!															n							No		y																		#DIV/0!			
TUH	42	1	63	1	04/12/16			-42472		1						N	FLT3-ITD	k = N ; m = FLT3-ITD ; IDH1	2	2				AML not otherwise specified		4	5.6	38	277.2	64	80	8093.9	nd	nd	nd	nd	nd	nd	138.4	100	38.4	177	7.9	2.2	nd	nd	2	1763	nd	nd	nd	nd			1	15/04/2016 ?	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	1	n			High			HE	Yes	High	y	nd	nd	nd	nd	nd	nd	nd	nd								45840	529351	11.5477966841187			
TUH	43	1	58		05/11/16			-42501		0						? 46,XY,t(8;21)(q22;q22)<12>/45,sl,-Y<7>/45,dsl,del(9)(q21q31)<2>	nd			0						2															0														0											#DIV/0!															n							No		n																293788.094	2103382.75	7.15952345570546	11		
TUH	44	1	19		05/10/16			-42500		0						? 45,X,-Y,T(8;21)(Q22;Q22)<11>/46,SL,+6<4>/46,XY<8>	nd			0						1															0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	45	2	58		05/13/16			-42503		0							nd			0																					0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	46	1	61		05/12/16			-42502		0						? 46,XY<20>	nd			0						1															0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	47	2	62.2465753424658	2	08/29/17				288	1	288	1	247	1	2	t(X;6) del9	nd	k = t(X;6) del9 ; m = nd		0	2	CMP				R	13	40	4.96	7	7										0								Autre	05/09/17	1	01/19/18	1	10/09/17	1	06/13/18										#DIV/0!															n							No		y																		#DIV/0!			
TUH	48	1	44.4246575342466	1	07/07/15	04/20/16		288	731	1	288	1	233	1	1	MLL-ELL t(11;19)	GATA2	k = MLL-ELL t(11;19) ; m = GATA2	2	0	3	GPMP		AML with recurrent genetic abnormalities (AML with other KMT2A rearrangements = AML with t(11;19))		2	11.7	137	15.6	5	36	510.1	2	23.7	50	47.4	23	nd	3.8	nd	nd	82	8.2	4.07	nd	nd	2.08	141	CTI	29/07/2015	1	11/21/16	1	08/31/15	1	07/07/17	2 cigarets a month	occasionally	commer??ant, tient un h??tel restaurant	no	no	no	no	76	1.75	24.8163265306122	no	no	no	no	no	no	no	no	no	no	no	no	no	1	n			Low			HE	Yes		n																376369.031	2269911.5	6.03107937432822	11		
TUH	49	2	79	2	06/01/16			-42522		1							nd			0																					0														1											#DIV/0!															n							No		y																		#DIV/0!			
TUH	50	2	74	2	06/21/16			-42542		1						46,XX,del(5)(p15p13),add(6)(q2?5),add(14)(q3?2)<17>/46,XX<4>	nd			3						1															0														1											#DIV/0!															n							No		n																		#DIV/0!			
TUH	51	2	78	2	06/29/16			-42550		0						46,XX,der(5)t(5;14)(q13;q12),der(14)t(5;14)(q15;q12)[2]/46,XX[18]	nd			0																					0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	52	1	22.3561643835616	1	08/29/16				2152	0	2152	0	2109	0	0	inv(16) tri8	FLT3-TKD ; PTPN11 ; SH2B3	k = inv16 tri8 ; m = FLT3 TKD ; PTPN11 ; SH2B3	1	1	1	GMP		AML with recurrent genetic abnormalities (AML with inv(16)) or AML with myelodysplasia-related cytogenetic abnormalities (AML with +8)		4	5	34	121.25	47	76	1804	nd	nd	nd	nd	nd	nd	6.3	nd	nd	98	3.7	3	nd	nd	4.37	3038	CTI	03/09/16	1	03/09/17	1	10/11/16	0	07/21/22	2,5 PA	occasionally	carreleur	no	no	no	no	60	nd	21	no	no	no	no	no	no	no	no	no	no	no	no	no	4	n						HE	Yes	Low	n																80152.875	1572514.25	19.6189375615036	44	49360	
TUH	53	2	60.1917808219178	1	09/11/16	05/12/17		243	308	1	243	1	207	1	1	N	FLT3-TKD ; NPM1	k = N ; m = FLT3 TKD ; NPM1 ; DNMT3A	1	0	2	MP2		AML with recurrent genetic abnomalities (AML with mutated NPM1)		4	8.6	76	163.53	16	34	1679	nd	nd	nd	nd	nd	nd	6.1	nd	nd	107	5.8	nd	nd	nd	0.71	754	CTI	13/09/2016	0		1	10/17/16	1	07/16/17	no	no	femme au foyer	no	no	no	no	nd	nd	37.1	no	no	no	yes	no	no	no	no	no	no	no	no	no	3	n			Low			HE	Yes	Low	n																		#DIV/0!			
TUH	54	2	56		09/20/16			-42633	262	1							nd			0																					0														1	06/09/17										#DIV/0!															n						NE	Yes		n																		#DIV/0!			
TUH	55	2	74	1	09/21/16	05/29/17		250		1						N	NPM1 ; TET2 ; DNMT3A	k = N ; m = FLT3-ITD ; NPM1	2	2				AML with recurrent genetic abnormalities (AML with mutated NPM1)		4	11.5	89	155	88	84	1627.2	nd	nd	nd	nd	nd	nd	7.2	nd	nd	91	5.6	5.6	nd	nd	1.19	671	CTI	09/23/16					1		no	no	nd	no	no	no	no	61	1.44	29.4174382716049	no	no	no	yes	no	yes	m??lanome	yes	pseudo-polyarthrite rhizom??lique	no	no	no	no	1	n						HE	Yes	Low	y																		#DIV/0!			
TUH	56	2	58.9835616438356	1	10/04/16	09/03/19		1064	1183	1	1064	1	1029	1	1	N	nd	k = N ; m = nd		0	2	MP2				2	10	141	21.73	9	84										0								CTI	05/10/16	0		1	11/08/16	1	12/31/19										#DIV/0!															n							No		y																		#DIV/0!			
TUH	57	1	79	1	08/05/16			-42587		1						tri13	NPM1 ; TET2 ; CEBPA	k = tri13 ; m = NPM1 ; FLT3-ITD	2	2				AML with recurrent genetic abnormalities (AML with mutated NPM1)		1	7.5	43	123	96	95	1864	nd	nd	nd	nd	nd	nd	21.5	13.4	8.1	91	7.8	2.92	nd	nd	0.92	187	CTI	08/06/16					1		no	no	nd	no	no	no	no	99	nd	nd	no	no	no	yes	yes	no	no	no	no	no	no	no	no	1	n			Low			HE	Yes	Low	y	nd	nd	nd	nd	nd	nd	nd	nd								65149.68	856499.75	13.146645539932	18	29402	
TUH	58	1	59		10/19/16			-42662	446	1						? 46,XY<23>	nd			0						2															0														1	01/08/18										#DIV/0!															n							No		n																		#DIV/0!			
TUH	59	1	63	1	12/22/16	07/12/17		202		1						N	IDH1 ; TET2 ; DNMT3A ; NRAS	k = N ; m = NPM1 ; IDH1	1	1				AML with recurrent genetic abnormalities (AML with mutated NPM1)		5	12	45	127	10	86	2372	nd	nd	nd	nd	nd	nd	42.7	38.2	4.5	98	4.2	2.22	nd	nd	1.45	836	CTI	12/23/16					1		30 PA	no	nd	no	no	no	no	81	1.73	27.0640515887601	no	no	yes	yes	yes	no	no	yes	art??riopathie +++	no	no	no	no	 1 - 2	n			Low			HE	Yes	High	n													Yes					#DIV/0!			
TUH	60	1	58.2109589041096	2	02/01/17				191	1	191	1	77	1	2		nd	k = nd ; m = nd		0	na	CMP				R	11.1	48	40.29	64.3	84										0								Autre	07/02/17	1	06/08/17	1	05/26/17	1	08/11/17										#DIV/0!															n							No		y																		#DIV/0!			
TUH	61	1	65.7780821917808	1	02/09/17				36	0	36	1				N	nd	k = N ; m = nd		0	2	GP				1	12.6	29	40.22	73	80										0								CTI	15/02/2017			0	03/17/17	0	03/17/17										#DIV/0!															n							No		n																		#DIV/0!			
TUH	62	1	78		02/15/17			-42781	22	1						? 50,XX,+4,+5,+8,+20<17>/46,XX<3>	nd			0						5															0														1	03/09/17										#DIV/0!															n							No		n																		#DIV/0!			
TUH	63	2	73	1	03/08/17			-42802		1	-42802	1				nd	nd	k = nd ; m = nd	0	0				nd		nd	6.1	55	72	56	nd	993.2	nd	nd	nd	nd	nd	nd	66	34	32	113	9.6	nd	nd	nd	nd	2682	no	no	no	no	0		1	03/09/17	no	no	nd	no	no	no	no	nd	nd	28.1	no	no	no	no	no	no	no	yes ?	d??ficit en prot??ine S	no	no	no	no	4	n						LE	Yes		n	nd	nd	nd	nd	nd	nd	nd	nd								50180.6	152313.36	3.03530368309665	71	51933	
TUH	63bis									0							nd			0																					0																									#DIV/0!																																								543217.563	1958206.875	3.60482982948031	6		
TUH	64	1	68		03/22/17			-42816		0						? 46,XY,t(8;21)(q22;q22),del19(q11q23)<14>/46,XY<1>	nd			0						2															0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	65	2	56		03/29/17			-42823		0							nd			0																					0														0											#DIV/0!															n							No		y																		#DIV/0!			
TUH	66	1	74		03/30/17			-42824		0							nd			0																					0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	67	2	74	2	09/21/16			-42634		1						N	NPM1 ; TET2 ; DNMT3A	k = N ; m = FLT3-ITD ; NPM1	2	2				AML with recurrent genetic abnormalities (AML with mutated NPM1)		4	11.5	89	155	88	84	1627.2	nd	nd	nd	nd	nd	nd	7.2	nd	nd	91	5.6	5.6	nd	nd	1.19	671	CTI	09/23/16					1		no	no	nd	no	no	no	no	61	1.44	29.4174382716049	no	no	no	yes	no	yes	m??lanome	yes	pseudo-polyarthrite rhizom??lique	no	no	no	no	3	n			Low			HE	Yes	Low	n													Yes			116675.52	257417.477	2.20626809291272	10		
TUH	68	1	38		06/01/17			-42887	31	1						46,XY,t(6;9)(p22;q34)<16>	nd			0						2															0														1	07/02/17										#DIV/0!															n							No		n																		#DIV/0!			
TUH	69	1	64	1	06/02/17	NA		#VALUE!		1						t(9;22)	ASXL1 ; RUNX1 ; SRSF2	k = t(9;22) ; m = BCR-ABL	3	3		Primitive CD34+CD117+CD13+CD33+MPO-		AML with recurrent genetic abnormalities (AML with t(9;22))	Progressed from MDS/MPN (LMC -> LMMC ?)	2ndR_SMP	11.8	36	172.2	38	32	83.7	nd	nd	nd	nd	nd	nd	7.1	nd	nd	124	4.6	3.75	nd	nd	1.88	1099	CTI	06/08/17					1		no	no	nd	no	no	no	no	nd	nd	40.2	no	no	no	yes	no	yes	LMC (avec suspicion LMMC)	yes	polyarthrite rhumato??de ; MGUS ?  IgG kappa ; insuffisance r??nale chronique ; SAOS	no	no	no	no	1	n			High	Low		HE	Yes	Low	n	19.39	7.85	47.23	27.84	10.83	0.71	6.54	8.14	2.96483180428135	2.38206388206388	7.2217125382263	5.8022113022113	Yes					#DIV/0!			
TUH	70	2	56		06/06/17			-42892		0						? 46,XX,inv(3)(q21q26)<20>	nd			0						4															0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	71	2	63.8465753424658	1	07/04/17	11/16/17		135	376	1	135	1	100	1	1	N	nd	k = N ; m = NPM1	1	0	2	MP3		AML with recurrent genetic abnomalities (AML with mutated NPM1)		5	7.5	32	168.76	8	28	3974	nd	nd	nd	nd	nd	nd	11.7	nd	nd	222	11.6	1.85	nd	nd	1.95	845	CTI	07/07/17	0		1	08/08/17	1	07/15/18	no	no	nd	no	no	no	no	nd	nd	28.6	no	no	no	no	no	no	no	no	no	no	no	no	no		n						NE	Yes		n																		#DIV/0!			
TUH	72	2	60.8657534246575	2	05/15/17				62	1	49	1				N	nd	k = N ; m = nd 		0	2	MP1				R	11.6	101	100.44	82	na										0								CTI	13/05/2017	0		0	07/03/17	1	07/16/17										#DIV/0!															n							No		n																		#DIV/0!			
TUH	73	2	50.1342465753425	1	08/03/17	03/16/18		225	410	1	225	1	192	1	1	NUP98 t(5;11) tri8	FLT3-ITD ; NRAS ; PTPN11 ; WT1	k = NUP98 t(5;11) tri8 ; m = FLT3-ITD ; NRAS ; PTPN11 ; WT1	3	0	3	MPP		AML with recurrent genetic abnormalities (AML with other rare recurring translocations - AML with t(5;11)) or AML with myelodysplasia -related cytogenetic abnormalities (AML wth +8)		2	9.7	84	118.46	82	80	298.2	2.4	44	60	73.3	nd	nd	3.7	nd	nd	67	6.5	4.7	nd	nd	1.66	1069	CTI	08/08/17	1	01/19/18	1	09/05/17	1	09/17/18	no	no	nd	no	no	no	no	52	nd	22	no	no	no	no	no	no	no	no	no	no	no	no	no	1	n			Low			HE	Yes	Low	n																14920.549	11256.028	0.754397710164686	10	97462	
TUH	74	1	58.5205479452055	1	09/08/17				16	1	16	1				N	nd	k = N ; m = nd		0	2	GP				1	11.6	67	298.5	96.9	92										0								CTI	08/09/17	0		0	ND	1	09/24/17										#DIV/0!															n							No		y																		#DIV/0!			
TUH	75	1	18.0712328767123	1	09/20/17				63	1	28	1				MLL-AF10	nd	k = MLL-AF10 ; m = nd	3	0	3	GMP		AML with recurrent genetic abnormalities (AML with other KMT2A rearrangements = AML with t(10;11))		1	8.8	30	87.28	83.1	92										0								CTI	23/09/2017	0		0	10/18/17	1	11/22/17										#DIV/0!															n							No		y																		#DIV/0!			
TUH	76	1	74.1780821917808	1	10/23/17				53	1	42	1				N	FLT3-ITD ; NPM1 ; DNMT3A ; TET2 ; CEBPA ; CBL	k = N ; FLT3-ITD ; NPM1 ; TET2 ; DNMT3A ; CEBPA ; CBL	2	2	2	GP		AML with recurrent genetic abnomalities (AML with mutated NPM1)	Progressed from MDS (TE) ???	1	6.6	15	128.45	92	93	1177.6	nd	nd	nd	nd	nd	nd	25	6	19	115	8.1	3	nd	nd	2.39	450	CTI	26/10/2017	0		0	12/04/17	1	12/15/17	no	no	poste	no	no	no	no	nd	nd	24.4	no	no	no	no	no	no	no	no	no	no	no	no	no	  1 - 2 - 3	n			High			HE	Yes	High	n													Yes			12577.139	6561.257	0.521681202696416	8	8918	
TUH	77									0										0																					0																									#DIV/0!																						No																				#DIV/0!			
TUH	78	2	64.2164383561644	2	11/16/17				241	1	70	1				t(7;17)	nd	k = t(7;17) ; m = nd 		0	2	CMP				R	7.9	89	26.89	56	80										0								Autre	18/11/2017	0		0	01/25/18	1	07/15/18										#DIV/0!															n							No		n																		#DIV/0!			
TUH	79	2	50.0356164383562	1	11/16/17	03/21/18		125	1568	0	125	1	83	1	1	N	nd	k = N ; m = NPM1 ; FLT3-ITD	2	0	2	MP1		AML with recurrent genetic abnormalities (AML with mutated NM1)		4	7	88	76.48	12.3	43	983.1	1.24	31	nd	100	19 ng/mL (25 OH) / 22 pg/mL (1-25 OH)	nd	4.2	nd	nd	71	5.3	3.1	nd	nd	0.83	706	CTI	11/21/17	1	04/19/18	1	12/28/17	0	03/03/22	1 package every day, since ??? ? 	no	blanchisseuse	no	no	no	no	47	nd	26	no	no	no	no	no	no	no	no	no	no	no	no	no	4	n						NE	Yes		n	nd	nd	nd	nd	nd	nd	nd	nd								69116.809	462816.711	6.69615275496877	34		
TUH	80	1	53.0794520547945	1	11/17/17	10/04/18		321	738	1	321	1	280	1	1	N	nd	k = N ; m = NPM1 ; IDH2 ; FLT3-TKD	1	0	2	MPP		AML with recurrent genetic abnormalities (AML with mutated NPM1)		2	8.2	26	86.11	80.9	71	783.9	1.6	41	nd	103	46 ng/mL (25 OH) / 92 pg/mL (1-25 OH)	nd	8	nd	nd	74	5.1	4.2	nd	nd	1.15	816	CTI	21/11/2017	1	01/31/19	1	12/28/17	1	11/25/19	40 PA	1 bottle of wine everyday	nd	no	no	no	no	81	nd	28.1	no	no	no	no	no	no	no	no	no	no	no	no	no	4	n						LE	Yes		n	nd	nd	nd	nd	nd	nd	nd	nd								64462.45	579370.617	8.98772257337411	11		
TUH	81	1	50.3369863013699	1	12/12/17	05/05/20		875	1521	0	875	1	847	1	1	inv(16) t(3;16)	FLT3-TKD ; NRAS ; KRAS	k = inv(16) t(3;16) ; m = FLT3 TKD ; NRAS ; KRAS	1	0	1	GMP		AML with recurrent genetic abnormalities (AML with inv(16))		4	9	40	66.58	54	61	1777.6	nd	nd	nd	nd	nd	nd	32	18	14	84	10.5	3	nd	nd	1.02	238	CTI	13/12/2017	1	07/26/18	1	01/09/18	0	02/10/22	no	no	agent de police municipale	no	no	no	no	nd	nd	29.2	no	no	no	no	no	no	no	no	no	no	no	no	no	3	n			Low			LE	Yes		n																		#DIV/0!			
TUH	82	2	68.6465753424658	1	02/20/18				160	1	132	1				2 clones: del10q/del9 del11 	TET2 ; NRAS ; ASXL1	k = 2 clones: del10q/del9q del11p => cmplx karyotype ; m = TET2 ; NRAS ; ASXL1	3	0	2	GPMP		AML with myelodysplasia-related gene mutations (ASXL1) or AML with myelodysplasia-related cytogenetic abnormalities (AML with cmplx karyotype)	Progressed from MDS/MPN (LMMC 1)	2ndR_SMP	8	29	41.82	55	81	373.1	nd	nd	nd	nd	nd	nd	4.4	nd	nd	48	8.5	4.82	nd	nd	2.54	538	CTI	22/02/2018	0		0	07/02/18	1	07/30/18	40 PA	yes, chronic ethylic intoxication, undetailed	infirmi??re dipl??m??e d'??tat en psychiatrie	no	no	no	no	nd	nd	17.6	no	no	no	no	no	yes	LMMC 1 ?  caryotype normal trait??e par hydrea	no	no	no	no	no	no	3	n			High			NE	Yes		y																		#DIV/0!			
TUH	83	2	51.0383561643836	1	03/01/18				1463	0	1463	0	1423	0	0	N	FLT3-ITD ; NPM1	k = N ; m = FLT3-ITD ; NPM1 ; DNMT3A	2	2	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)		4	6.2	19	97.46	29	84	546.8	1.49	34	nd	92	nd	nd	2	nd	nd	109	8.5	3.2	nd	nd	1.89	958	CTI	02/03/18	1	07/25/18	1	04/10/18	0	03/03/22	no	no	secr??taire m??dicale dans cabinet de kin??	no	no	no	no	57	nd	nd	no	no	no	no	no	no	no	no	no	no	no	no	no	2	n			High	Low		HE	Yes		y	27	11.35	52.35	25.35	10.49	5.16	15.84	18.91	1.70454545454545	1.42781597038604	3.30492424242424	2.7683765203596				96212.673	704100.973	7.31817286689457	8		
TUH	84	1	69.6931506849315	1	03/12/18				0	1	0	1				N	FLT3-ITD ; NPM1 ; DNMT3A	k = N ; m = FLT3-ITD ; NPM1 ; DNMT3A	2	2	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)		5	5.8	66	280.87	33	34	11436.3	nd	nd	nd	nd	nd	nd	20	9	11	170	14.8	nd	nd	nd	nd	3609	BSC		0		0	ND	1	03/12/18	yes, undetailed	no	nd	no	no	no	no	nd	nd	29.4	yes	DT2	no	yes	no	no	no	no	no	no	no	no	no	2	n			High	Low		HE	Yes		y	30.71	8.85	45.28	14.57	13.24	8.62	11.93	17.52	2.57418273260687	1.75285388127854	3.79547359597653	2.58447488584475						#DIV/0!			
TUH	85	1	38.4876712328767	1	03/28/18				568	0	568	0	526	0	0	inv(16) tri22	nd	k = inv16 tri22 tri4 tri13 ; m = 0	1	0	1	CMP		AML with recurrent genetic abnormalities (AML with inv(16))		4	9.1	31	41.17	12	24	1293	1.8	40	45	88.9	9	nd	10	nd	nd	128	5.3	4.4	nd	nd	2.21	654	CTI	31/03/2018			1	05/09/18	0	10/17/19	20 PA (and occasionnally, cannabis)	occasionally	travaille dans une entreprise de plomberie/chauffagerie	no	no	no	no	100	nd	nd	no	no	no	no	no	no	no	no	no	no	no	no	no		n						NE	Yes		y																		#DIV/0!			
TUH	86	2	67.5945205479452	2	06/04/18	02/12/19		253	530	1	253	1	78	1	1	N	FLT3-TKD ; NPM1 ; IDH2 ; DNMT3A	k = N ; m = FLT3-TKD ; NPM1 ; IDH2 ; DNMT3A	1	0	2	GP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		4	10.9	84	109.93	97	na	326.4	nd	nd	nd	nd	nd	nd	6.3	nd	nd	64	5.1	4.6	nd	nd	1.18	353	VDZ		0		1	11/26/18	1	11/16/19	no	no	cadre chez airbus	no	no	no	no	nd	nd	nd	no	no	no	no	no	yes	tumeur b??nigne sein G	no	no	no	no	no	no	3	n			Low	Low		HE	Yes	Low	n	25.8653274444444	0.629741888888889	79.2865876666667	53.4212602222222	9.75048488888889	15.4851006666667	4.83	11.77	5.35514025764894	2.19756392900972	16.4154425810904	6.73632860379496	Yes					#DIV/0!			
TUH	87	2	23.5260273972603	1	06/27/18	04/28/20		671	1464	0	671	1	635	1	1	N	NPM1 ; PHF6	k = N ; m = NPM1 ; FLT3-ITD ; PHF6	2	2	2	MP2		AML with recurrent genetic abnomalities (AML with mutated NPM1)		5	8	49	268.69	73	78	1998	nd	nd	nd	nd	nd	nd	9.5	nd	nd	71	4.8	1.42	nd	nd	0.93	1545	CTI	30/06/2018	1	05/02/19	1	08/02/18	0	06/30/22	no	no	??tudiante allemande en France	no	no	no	no	57	1.68	20.1955782312925	no	no	no	no	no	no	no	no	no	no	no	no	no	3	n				High		HE	Yes	Low	y	43.15	16.7	123.48	80.33	16.25	10.18	14.11	17.58	3.05811481218994	2.45449374288965	8.7512402551382	7.02389078498294	Yes					#DIV/0!			
TUH	88	2	43.3232876712329	1	07/02/18	06/03/19		336	1414	0	336	1	291	1	1	N	FLT3-TKD ; NPM1 ; DNMT3A	k =  N ; m = FLT3-ITD ; FLT3 TKD ; NPM1 ; DNMT3A	2	0	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)		5	8.1	67	96.59	70	91	595.9	1.36	33	nd	98	19 ng/mL (25 OH) / 100 pg/mL (1-25 OH)	nd	3.4	nd	nd	54	10.7	3.79	nd	nd	0.89	1284	CTI	03/07/18	1	08/14/19	1	08/16/18	0	05/16/22	5 PA	occasionally	administration d'une ??cole de commerce	no	no	no	no	61	nd	21.8	no	no	no	no	no	no	no	no	no	no	no	no	no	3	n			Low	Low		HE	Yes	Low	y	21.72	1.89	31.94	10.22	8.41	11.4	13.51	16.62	1.60769800148038	1.30685920577617	2.36417468541821	1.92178098676294	Yes			75083.977	633993.008	8.44378565615937	10		
TUH	89	2	44		07/17/18			-43298		0							nd			0																					0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	90	1	77.6821917808219	1	07/18/18				57	1	57	1				N	NPM1 ; IDH2	k = N ; m = FT3-ITD ; NPM1 ; IDH2	2	2	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)		2	9.8	151	11.14	73	71	1387.3	nd	nd	nd	nd	15	4.57	12	nd	nd	99	12.6	2.2	nd	nd	1.67	1144	VDZ	10/08/18	0		0	ND	1	09/13/18	no	no	nd	no	no	no	no	74	1.72	25.013520822066	yes	DT2	no	no	no	no	no	no	no	no	no	no	no	1	n			High			HE	Yes	High	y																58414	470010	8.04618755777724			
TUH	91	1	67.6328767123288	1	08/09/18				39	1	39	1				N	nd	k = N ; m = nd		0	2	CMP				5	11.5	15	31.01	64	82								5.2	nd	nd	88	6.2	1.56	nd	nd	0.88	330	CTI	16/08/2018	0		0	ND	1	09/17/18	40 PA	no	gendarme	no	no	no	no	112	1.82	33.8123415046492	no	no	no	no	no	no	no	no	no	no	no	no	no		n						NE	Yes		y																18909.707	75656.086	4.0009126529565	15		
TUH	92	1	68.4767123287671	1	08/16/18	02/15/19		183	321	1	183	1	151	1	1	N	nd	k = N ; m = FLT3-ITD ; NPM1 ; DNMT3A	2	0	2	MP1		AML with recurrent genetic abnormalities (AML with mutated NPM1)		5	11.4	46	68.64	54	59	5718	1.1	25.6	28	93.1	15	nd	69.1	63	6.09999999999999	94	9.3	2.69	nd	nd	1.12	980	CTI	17/08/2018	0		1	09/17/18	1	07/03/19	20 PA	no	no	no	no	no	no	84	1.76	27.1177685950413	no	no	no	no	no	yes	polypes coliques ? ; polype caecal -> ad??nome tubuleux en dysplasie de bas grade	no	no	no	no	no	no	4	n						LE	Yes		y	nd	nd	nd	nd	nd	nd	nd	nd								61089.96	651528.34	10.6650641120079	10		
TUH	93	2	65.1013698630137	1	08/16/18				24	1	24	1				N	FLT3-ITD ; FLT3-TKD ; NPM1 ; DNMT3A ; SH2B3	k = N ; m = FLT3ITD ; FLT3-TKD ; NPM1 ; DNMT3A ; SH2B3 ; IDH2	2	2	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	11.2	85	176.98	90	93	1013	nd	nd	nd	nd	18	nd	4.1	nd	nd	69	9.4	4.68	nd	nd	2.96	461	CTI	17/08/2018	0		0	ND	1	09/09/18	no	no	no	no	no	no	no	nd	nd	23.7	no	no	no	no	no	no	no	no	no	no	no	no	no	 2 - 3	n			Low			HE	Yes	Low	y	19.63	8.69	47.99	28.35	8.85	2.09	4.96	8.16	3.95766129032258	2.40563725490196	9.67540322580645	5.88112745098039	Yes			68121.712	341721.636	5.01633951888937	15		
TUH	94	2	75.3342465753425	1	09/28/18				522	0	522	0	480	0	0	N	nd	k = N ; m = ASXL1 ; NPM1	3	0	2	MP3		AML with recurrent genetic abnormalities (AML with mutated NPM1) or AML with myelodysplasia-related gene mutations (AML with mutated ASXL1)	Progressed from MDS/MPN (LMMC)	2ndR_SMP	10.5	103	197.47	39	32	11265	nd	nd	nd	nd	nd	nd	21	11	10	181	7	2.5	nd	nd	1.38	> 4000	CTI	04/10/18			1	11/09/18	0	03/03/20	40 PA	no	tourneur m??canicien, travaillait ?  l'usine	no	no	no	no	nd	nd	26.5	no	no	no	yes	yes	yes	LMMC ; ad??nome prostatique	yes	AOMI	no	no	no	no		n				Low		NE	Yes		n																		#DIV/0!			
TUH	95	2	46.9068493150685	1	11/12/18	07/03/19		233	922	1	233	1	196	1	1	inv(16) tri9 tri13	nd	k = inv(16) tri9 tri13 ; m = nd	1	0	1	GMP		AML with recurrent genetic abnormalities (AML with inv(16))		5	6.6	20	66.64	75	80										0								CTI	16/11/2018	1	10/10/19	1	12/19/18	1	05/22/21										#DIV/0!															n							No		y																		#DIV/0!			
TUH	96	2	54.3287671232877	1	11/14/18	09/13/21			1266	0	1034	1	998	1	1	tri4	FLT3-ITD ; NPM1 ; IDH1 ; IDH2 ; DNMT3A	k = tri4 ; m = FLT3-ITD ; NPM1 ; IDH1 ; IDH2 ; DNMT3A ; FLT3-TKD	2	2	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	12.1	157	88.2	93	93	49.7	2.25	18	nd	33	nd	nd	5	nd	nd	90	8.4	5	nd	nd	0.74	679	CTI	16/11/2018	1	04/24/19	1	12/20/18	0	05/03/22	no	no	secr??taire dans un cabinet de notaire	no	no	no	no	65.1	1.65	23.9118457300275	no	no	no	no	no	no	no	no	no	no	no	no	no	2	n			Low			HE	Yes		y																		#DIV/0!			
TUH	97	2	71.041095890411	1	12/09/18				1346	0	1346	0	1306	0	0	t(9;22)	NPM1	k = t(9,22) ; m = NPM1	3	3	3	EB		AML with recurrent genetic abnomalities (AML with mutated NPM1 or AML with t(9;22)))		6	12.2	84	92.73	63	89	208.9	nd	nd	nd	nd	nd	nd	10	nd	nd	58	5.9	2.96	nd	nd	1.04	185	CTI	13/12/2018			1	01/18/19	0	08/16/22	no	no	nd	no	no	no	no	nd	nd	26.3	no	no	no	no	no	no	no	no	no	no	no	no	no	3	n			Low			HE	Yes		n																		#DIV/0!			
TUH	98	1	57.7835616438356	1	12/31/18	10/19/20		658	1117	1	658	1	615	1	1	N	nd	k = N ; m = nd 		0	2	CMP				4	8.5	39	123.51	63	48										0								CTI	04/01/19	0		1	02/12/19	1	01/21/22										#DIV/0!															n							No		n																		#DIV/0!			
TUH	99	1	65.1534246575343	1	01/02/19				14	1	14	1				N	IDH2	k = N ; m = ASXL1 ; IDH2 ; JAK2 V617F	3	2	2	MPP		AML with myelodysplasia-related gene mutations (AML with mutated ASXL1)	Progressed from MDS (my??lofibrose primitive) ?? Germline predisposition due to JAK2 variants ? 	na	7.7	38	196.83	91	na	450	nd	nd	nd	nd	11	nd	16	4	12	125	6.5	3.1	nd	nd	2.47	506	BSC		0		0	ND	1	01/16/19	yes, undetailed	nd	pi??ces d??tach??es ?  Orly	no	no	no	no	nd	nd	28	no	no	no	yes	no	yes	myelofibrose primitive avec JAK2 mut??e	yes	BPCO post-tabagique	no	no	no	no	3	n			High	Low		HE	Yes	Low	n	13	9.20712567	29.1872125	15.8953811	4.02574592	0.05895983	2.85	8.88	4.56140350877193	1.46396396396396	10.2411271929825	3.2868482545045				5348.648	17761.328	3.32071357098093	12	3877	
TUH	100	1	76.9561643835616	1	01/04/19	09/18/19		257	348	1	257	1	218	1	1	N	nd	k = N ; m = nd		0	2	MP1				1	9.8	39	136.91	91	88										0								CTI	10/01/19	0		1	02/12/19	1	12/18/19										#DIV/0!															n							No		n																		#DIV/0!			
TUH	101	2	69.9945205479452	1	03/27/19				43	1	27	1				Cx	nd	k = cmplx ; m = TP53	3	3	3	MPP		AML with myelodysplasia-related cytogenetic abnormalities (cmplx karyotype) or AML with mutated TP53		2	5.9	43	107.6	63	85								10.7	nd	nd	62	5.3	3.05	nd	nd	1.28	758	CTI	05/04/19	0		0	04/23/19	1	05/09/19	no	no	??ducatrice, psychologue dans le milieu hospitalier ;  dans les assurances	no	no	no	no	nd	nd	24.7	no	no	no	no	no	yes	fibromes ut??rins ; polypes coliques b??nins	no	no	no	no	no	no		n						LE	Yes		y																41944.025	323799.201	7.71979324826361	21	15373	
TUH	102	1	77.558904109589	1	04/05/19	08/06/19		123	192	1	123	1	76	1	1	N	NPM1	k = N ; m = NPM1	1	2	2	GP		AML with recurrent genetic abnomalities (AML with mutated NPM1)	Progressed from MDS ??? (thrombop??nie inexpliqu??e) ; therapy-related (K de prostate ; melanome) ???	4	8.7	34	135.16	71	68	3823.1	1.39	29	nd	85	17	nd	9	nd	nd	154	7.4	2.8	nd	nd	3.22	649	CTI	11/04/19	0		1	05/22/19	1	10/14/19	no	no	employ?? de la poste	no	yes K de prostate et m??lanome	no	no	60	nd	20.9	no	no	no	no	no	yes	MDS (thrombop??nie non expliqu??e) ?? ; K de la prostate ; m??lanome	no	no	no	no	no	no	2	n			High			HE	Yes	High	n																52325.81	521056.271	9.95792078517275	13	18412	
TUH	103	1	78.2739726027397	2	04/15/19				165	1	146	1				tri4	nd	k = tri4 ; m = FLT3-TKD ; NPM1	1	0	2	MP1		AML wth recurrent genetic abnormalities (AML with mutated NPM1)		R	8.1	51	1.24	3	53								6	nd	nd	106	7.8	2.7	nd	nd	1.28	429	Autre	13/05/2019	0		0	09/08/19	1	09/27/19	20 PA	no	dans les travaux publics	no	no	no	no	61	nd	24.5	no	no	no	yes	no	no	no	no	no	no	no	no	no		n							No		y																39877.477	491498.509	12.3252157853417	12		
TUH	104	1	45.5506849315069	1	04/17/19	10/28/19		194	1142	0	194	1	160	1	1	N	NPM1 ; IDH1 ; DNMT3A	k = N ; m = NPM1 ; IDH1 ; DNMT3A	1	2	2	MP3		AML with recurrent genetic abnomalities (AML with mutated NPM1)		5	7.4	264	60.21	51	56	1079.3	1.64	13	nd	31	14	2.48	5	nd	nd	80	4.5	3.2	nd	nd	2.04	635	CTI	19/04/2019	1	03/24/20	1	05/21/19	0	06/02/22	no	no	nd	no	no	no	no	78	nd	25.8	no	no	no	no	no	no	no	no	no	no	no	no	no		n						HE	Yes		y																329202.747	2140641.857	6.50250302133718	16		
TUH	105	1	64.7369863013699	1	04/21/19	10/08/19		170	731	0	170	1	133	1	1	N	NPM1	k = N ; m = NPM1	1	2	2	MP1		AML with recurrent genetic abnomalities (AML with mutated NPM1)	Progressed from MDS/MPN (mastocytose syst??mique)	2	12.7	81	42.03	29	37	854	nd	nd	nd	nd	17	0.79	5.8	nd	nd	124	5.7	4.28	nd	nd	2.57	634	CTI	26/04/2019	1	09/19/19	1	05/28/19	0	04/21/21	90 PA	no	??beniste	no	no	no	no	77	1.64	28.6287923854848	no	no	no	no	no	yes	SMP avec mastocytose syst??mique indolente avec h??patospl??nom??galie, ost??ocondensation punctiforme diffuse, nodules pulmonaires, nodules thyro??diens, polynucl??ose neutrophile et ??osinophile	yes	mastocytose syst??mique	no	no	no	no	3	n			High			HE	Yes		y																		#DIV/0!			
TUH	106	2	47.186301369863	1	04/23/19				1157	0	1157	0	1122	0	0	N	FLT3-ITD ; NPM1	k = N ; m = FTL3-ITD ; NPM1	2	2	2	GP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	9.2	64	102.26	95.9	97	317.4	1.55	13	nd	33	nd	nd	6	nd	nd	61	12.3	5.8	nd	nd	1.14	346	CTI	25/04/2019	1	03/16/21	1	05/28/19	0	06/23/22	no	no	nd	no	no	no	no	102	nd	36.1	yes	DT2	no	yes	no	no	no	yes	purpura rhumato??de ; insuffisance veineuse chronique	no	no	no	no	4	n						LE	Yes		y																13788	212966	15.4457499274732	3	1842	
TUH	107	2						0		0							nd			0																					0														0											#DIV/0!															n							No		y																75939.79	432897.019	5.7005295774455	62	17153	
TUH	108	2	71.3945205479452	1	05/07/19				4	1	4	1				tri8 tri8 t(1;11) -> cmplx karyotpe	nd	k = cmplx (tri8 tri8 t(1;11)..) ; m = 0	3	3	3	MP3		AML with myelodysplasia-related cytogenetic abnormalities (cmplx karyotype)	Progressed from MDS/MPN ?? (mastocytose syst??mique)	5	12.9	17	38.76	26.1	95								23	3	20	73	19.8	3.1	nd	nd	3.12	> 4000	CTI	09/05/19	0		0	ND	1	05/11/19	no	no	nd	no	no but immunotherapy with LYTAC	no	no	67	nd	23.7	yes	DT2	no	yes	no	yes	MGUS (gammapathie monoclonale de signification ind??termin??e) IgG lambda non trait??e ; mastocytose syst??mique trait??e	yes	pneumopathie interstitielle non ??tiquet??e ; mastocytose syst??mique	no	no	no	no		n							No		n																25791.308	480964.743	18.6483269092052	13	69050	
TUH	109	1	65.0438356164384	1	05/12/19				1144	0	1144	0	1108	0	0	N	NPM1 ; DNMT3A	k = N ; m = NPM1 ; DNMT3A	1	2	2	MP2		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	13	105	94.03	51	66	2085	nd	nd	nd	nd	27	nd	7.5	nd	nd	176	5.7	4.73	nd	nd	2.98	669	CTI	16/05/2019			1	06/17/19	0	06/29/22	no	no	nd	no	no	no	no	67	1.73	22.3863142771225	no	no	no	no	yes	no	no	no	no	no	no	no	no	3	n			Low			HE	Yes		y																22555.542	392082.614	17.3829834813989	15	54329	
TUH	110	2	81.4684931506849	1	05/10/19				29	1	29	1				N	FLT3-ITD ; FLT3-TKD ; NPM1 ; IDH1	k = N ; m = FLT3-ITD ; FLT3-TKD ; NPM1 ; IDH1	2	2	2	CMP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	5.9	18	144.2	98	93	1095.7	nd	nd	nd	nd	37	2.91	5.9	nd	nd	55	7.3	2.99	nd	nd	2.94	1493	VDZ	27/05/2019	0		0	ND	1	06/08/19	no	no	nd	no	no	no	no	55	1.58	22.0317256849864	no	no	no	yes	no	no	no	no	no	no	no	no	no	3	n			High			HE	Yes		n																22768	601688	26.4269149683767	47		
TUH	111	2						0		0							nd			0																					0														0											#DIV/0!															n						HE  masse	Yes		y																21891.326	308663.686	14.0998167950174	20	29241	
TUH	112	1	38.9835616438356	1	06/13/19	08/13/20		427	647	1	427	1	378	1	1	N	nd	k = N ; m = nd		2	2	CMP				2	8.4	19	1.63	1	36										0								CTI	21/06/2019	1	10/20/19	1	08/01/19	1	03/21/21										#DIV/0!															n							No		y																		#DIV/0!			
TUH	113	2	60.3972602739726	1	06/17/19				907	0	907	0	871	0	0	t(8;21) delX del9q	nd	k = t(8;21) delX del9q ; m = nd	1	0	1	GMP				2	8.1	18	15.58	48.8	40										0								CTI	21/06/2019			1	07/23/19	0	12/10/21										#DIV/0!															n							No		y																		#DIV/0!			
TUH	114	1						0		0							nd			0																					0														0											#DIV/0!															n							No		y																35002.092	283349.802	8.09522476542259	9	12283	
TUH	115	1	73.1917808219178	1	04/04/19				270	1	82	1				del7	nd	k = del7 ; m = nd	3	0	3	MPP		AML with myelodysplasia-related cytogenetic abnormalities (del7)	Progressed from MDS/MPN	2ndR_SMP	6.5	241	2.53	13	61										0								VDZ	18/04/2019	0		0	06/25/19	1	12/30/19										#DIV/0!															n							No		y																		#DIV/0!			
TUH	116	2	67.6904109589041	1	03/11/19				894	1	63	1				Mono Cx	nd	k = monosomal ; m = nd	3	0	3	CMP			Progressed from MDS/MPN	2ndR_SMP	11.4	583	1.16	48.2	31										0								VDZ	18/03/2019	1	11/28/19	0	05/13/19	1	08/21/21										#DIV/0!															n							No		y																		#DIV/0!			
TUH	117	2	52.7232876712329	1	07/03/19	03/09/20		250	1084	0	250	1	200	1	1	N	NPM1 ; DNMT3A	k = N ; m = FLT3-TKD ; NPM1 ; DNMT3A	1	2	2	MP3		AML with recurrent genetic abnomalities (AML with mutated NPM1)		5	5	29	272.49	91	85								21.6	10.8	10.8	68	8.5	3.41	nd	nd	2.88	1241	CTI	06/07/19	1	04/17/20	1	08/22/19	0	06/21/22	20 PA	no	secr??taire m??dicale en laboratoire	no	no	no	no	nd	nd	24.1	no	no	no	no	no	no	no	no	no	no	no	no	no		n						LE	Yes		y																10468.667	557381.515	53.2428355014063	15	66511	
TUH	118	2						0		0							nd			0																					0														0											#DIV/0!															n							No		y																		#DIV/0!			
TUH	119	2	75.2684931506849	1	08/23/19				125	1	81	1				N	FLT3-ITD ; NPM1 ; DNMT3A	k = N ; m = FLT3-ITD ; NPM1 ; DNMT3A	2	2	2	CMP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		1	7.9	129	154.43	87.3	91	767.2	nd	nd	nd	nd	nd	nd	6	nd	nd	47	7.4	3.1	nd	nd	0.99	1251	CTI	28/08/2019	0		0	11/12/19	1	12/26/19	no	no	employ??e de maison	no	no	no	no	nd	nd	22	no	no	no	no	no	no	no	yes	asthme	no	no	no	no	3	n			High	Low		HE	Yes	High	y	23	6.597246	67.708174	44.2965533	5.40725775	11.4071169	6.21	11.85	3.7037037037037	1.94092827004219	10.9030876006441	5.71376995780591				13480.488	21521.785	1.5965137908954	11	2245	
TUH	120	2	64.7123287671233	1	10/22/19	01/08/21		444	625	1	444	1	403	1	1	inv(16) tri8 tri22	nd	k = inv16 tri8 tri22 ; m = FLT3-TKD	1	2	1	GMP		AML with recurrent genetic abnormalities (AML with inv(16))		1	11.4	268	10.87	66	83								< 2,5	nd	nd	77	4.7	4.73	nd	nd	2.72	889	CTI	28/10/2019	1	10/06/20	1	12/02/19	1	07/08/21	15 PA	no	secr??taire m??dicale en h??matologie puis attach??e de direction au CHU	no	no	no	no	nd	nd	nd	no	no	no	no	no	no	no	yes	rectocolite h??morragique	no	no	no	no		n							No		y																135375	497616	3.67583379501385	55	38893	
TUH	121	2	77.2328767123288	2	09/02/19				148	1	120	1				del7q tri21	IDH1	k = t(1;7) avec del7q tri1q tri21 ; m = 0	3	3	3	MPP		AML with myelodysplasia-related cytogenetic abnormalities (del7q)	Progressed from MDS/MPN (thrombocyt??mie essentielle)	R	11.8	459	4.54	18	21								6	nd	nd	70	6	4.8	nd	nd	1.9	414	Autre	07/10/19	0		0	12/31/19	1	01/28/20	no	no	no	no	no mais SMP trait?? par hydrea	no	no	65	nd	nd	no	no	no	no	no	yes	SMP ( thrombocyt??mie essentielle)	no	no	no	no	no	no		n						HE	Yes		y																146782	1008388	6.86997043234184	15	52357	
TUH	122	1	63.9506849315069	1	10/09/19				965	0	965	0	841	0	0	N	nd	k = N ; m = nd		0	2	MPP			Progressed from MDS/MPN	2ndR_SMP	13.8	152	1.55	0	37										0								CTI	14/11/2019	1	04/27/20	1	02/10/20	0	05/31/22										#DIV/0!															n							No		y																		#DIV/0!			
TUH	123	2	75.5917808219178	1	11/06/19				136	1	67	1				N	nd	k = N ; m = SF3B1 ; FLT3-TKD ; NRAS	3	2	2	MPP		AML with myelodysplasia-related gene mutations (AML with mutated SF3B1)	Progressed from MDS/MPN (LMMC-1)	2ndR_SMP	11.4	323	71.72	20	42								14	nd	nd	41	5.2	2.8	nd	nd	1.71	1243	VDZ	10/12/19	0		0	01/12/20	1	03/21/20	no	no	agricultrice	no	LMMC-1 trait??e par EPO	no	no	50	nd	19.2	no	no	no	yes	no	yes	fibrome uterin ; my??lodysplasie de type an??mie sid??roblastique puis LMMC-1	no	no	no	no	no	no		n						LE	Yes		y																139321	1459933	10.4789155977921	10		
TUH	124	1	70.7917808219178	1	10/23/19				121	1	75	1				tri8 tri9	nd	k = tri8 tri9 ; m = nd		0	2	CMP			Progressed from MDS/MPN	2ndR_SMP	9.4	20	12.14	25	44										0								CTI	07/11/19	0		0	01/06/20	1	02/21/20										#DIV/0!															n							No		y																		#DIV/0!			
TUH	125	1	30.1013698630137	1	11/12/19	09/09/20		302	446	1	99	1				t(6;9) DEK-NUP214 t(3;9;12;15)	NPM1 ; IDH1 ; DNMT3A	k = t(6;9) DEK-NUP214 t(3;9;12;15) ; m = NPM1 ; IDH1 ; DNMT3A	3	0	3	CMP		AML with recurrent genetic abnomalities (AML with mutated NPM1)		2	10.9	23	5.37	29	24										0								CTI	22/11/2019	1	08/04/20	0	02/19/20	1	01/31/21										#DIV/0!															n							No		y																		#DIV/0!			
TUH	126	1	61.8493150684932	1	11/06/19	03/29/21		509	979	0	509	1	448	1	1	N	nd	k = N ; m = DNMT3A ; NPM1 ; IDH1	1	2	2	MP3		AML with recurrent genetic abnormalities (AML with mutated NPM1)		5	8.5	133	3.8	4	37								4	nd	nd	161	7.7	1.45	nd	nd	2.86	354	CTI	26/11/2019			1	01/06/20	0	07/12/22	10 PA	no	agent de ma??trise au conseil d??partemental de l'aveyron	no	no	radioth??rapie pour s??minome testiculaire	no	81	1.7	28.0276816608996	no	no	no	yes	no	yes	s??minome testiculaire	no	no	no	no	no	no		n							No		y																779451	1361310	1.74649849701906	14		
TUH	127	2	69.7561643835616	1	11/15/19	05/26/20		193	251	1	193	1	127	1	1	N	nd	k = N ; md = nd		0	2	GMP				2	11.1	64	2.59	0	45										0								CTI		0		1	01/20/20	1	07/23/20										#DIV/0!															n							No		y																		#DIV/0!			
TUH	128	2	68.7424657534247	1	11/29/19				481	0	481	0	435	0	0	2 mar min MYC	nd	k = 2 mar min MYC ; m = 0	2	2	2	GMP		AML not otherwise specified		2	7.6	86	56.4	78.8	52	175.5	nd	nd	nd	nd	nd	nd	4	nd	nd	59	5.1	4.9	nd	nd	0.87	352	CTI	05/12/19			1	01/14/20	0	03/24/21	no	no	femme au foyer	no	no	no	no	nd	nd	21.4	no	no	no	yes	yes	no	no	no	no	yes	no	no	no	3	n			Low			NE	Yes		y																		#DIV/0!			
TUH	129	1	68.7041095890411	1	12/17/19	04/24/20		129	389	1	129	1	100	1	1	N	nd	k = N ; m = NPM1 ; IDH1 ; FLT3-TKD	1	2	2	MP2		AML with recurrent genetic abnormalities (AML with mutated NPM1)		5	11.3	60	178.13	92	89								7.5	nd	nd	147	7.5	2.43	nd	nd	1.83	1699	CTI	21/12/2019	0		1	01/15/20	1	01/09/21	no	no	nd	no	no	no	no	76	1.7	26.3	no	no	no	yes	no	yes	ad??nome prostatique	no	no	no	no	no	no		n						HE	Yes		n																79506.816	1421228.633	17.8755571472011	22	52084	
TUH	130	1	70.5178082191781	1	11/21/19				30	1	30	1				t(3;18)	nd	k = t(3;18) ; m = ASXL1	3	2	2	MP3		AML with myelodysplasia-related gene mutations (AML with mutated ASXL1)	Progressed from MDS (SMD EB1 puis SMD EB2)	2ndR_MDS	9.9	11	3.48	0	91	1205.7	nd	nd	nd	nd	20	3.17	10.7	nd	nd	633	11.7	0.97	nd	nd	1.2	994	BSC		0		0	ND	1	12/21/19	50 PA	no	peintre dans le batiment	no	vidaza dans le cadre de son SMD EB2	no	no	87	1.68	30.8248299319728	no	no	yes	yes	yes	yes	SMD EB1 puis SMD EB2 trait?? par VIDAZA et EPO	no	no	no	no	no	no	3	n			Low			HE	Yes		n																19681.371	368758.344	18.7364154661787	290	67501	
TUH	131	2	74	1						0						N	NPM1 ; TET2 ; DNMT3A	k = N ; m = NPM1 ; FLT3-ITD	2	2				AML with recurrent genetic abnormalities (AML with mutated NPM1)		4	8.6	64	235.4	84	nd	2214	nd	12.5	nd	nd	nd	nd	11.6	nd	nd	74	6.5	2.66	nd	nd	1.44	1888							0											#DIV/0!															y			Low			HE	Yes	Low	n																		#DIV/0!			
TUH	132	2	82	1						1	40631	1				N	nd	k = N ; m = FLT3-ITD ; NPM1	2	2				AML with recurrent genetic abnormalities (AML with mutated NPM1)		1	9	52	106	85.1	98	nd	nd	16.7	nd	nd	nd	nd	6.1	nd	nd	106	7.8	6.95	nd	nd	3.5	1138	BSC		0		0	ND	1	03/29/11	no	no	assistante sociale	no	no	no	no	59	1.69	20.6575400021008	no	no	no	yes	no	yes	fibrome ut??rin	no	no	no	no	no	no	1	y			High			HE	Yes	Low	n																		#DIV/0!			
TUH	133	1		1						0						46,XY	nd			2						4															0														0											#DIV/0!															y						HE	Yes	Low	n																		#DIV/0!			
TUH	134	2	58	1						1	40883	1	321	1	2	tri10	CEBPA ; NRAS ; EZH2 ; IKZF1 ; GATA2	k = tri10 ; m = CEBPA	2	2				AML not otherwise specified		1	5.7	200	182	90	85	481	nd	nd	nd	nd	nd	nd	8.1	nd	nd	59	5.9	5.38	nd	nd	1.68	1827	CTI	??/12/2010	0		1	01/19/11	1	12/06/11	no	1-2 glasses everyday	secr??taire employ??e de bureau	no	no	no	no	59	1.62	22.4813290656912	no	no	no	no	no	yes	fibrome ut??rin	no	no	no	no	no	no	1	y			Low			HE	Yes	High	n																		#DIV/0!			
TUH	135	2	38	1						0	0	0	-39666	0	0	N	FLT3-TKD ; NPM1 ; IDH1 ; NRAS ; PTPN11	k = N ; m = NPM1	1	2				AML with recurrent genetic abnormalities (AML with mutated NPM1)		1	10.7	162	85.5	98	90	165	nd	21	nd	nd	nd	nd	3.5	nd	nd	67	6.1	3.87	nd	nd	0.83	2040	CTI	??/06/2008	0		1	08/06/08	0											#DIV/0!														1	y			Low			HE	Yes	High	n																		#DIV/0!			
TUH	136	2		1						0						46,XX	FLT3-TKD ; NPM1 ; GATA2 ; WT1 ; SH2B3			2						1															0														0											#DIV/0!														1	y			Low			HE	Yes	High	n																		#DIV/0!			
TUH	137	1		1						0	0	0	-40540	0	0	N	NPM1 ; TET2	k = N ; m = NPM1 ; FLT3-ITD	2	2				AML with recurrent genetic abnormalities (AML with mutated NPM1)		1	11.6	46	132	91	94	723	nd	19.8	nd	nd	nd	nd	3	nd	nd	77	5.5	3.21	nd	nd	1.59	1188	CTI	??/11/2010	0		1	12/28/10	0											#DIV/0!				yes										1	y			Low			HE	Yes	Low	n																		#DIV/0!			
TUH	138	2		2						0						46,XX	TET2 ; DNMT3A ; TP53 ; JAK2			2						2															0														0											#DIV/0!															y						HE	Yes	High	n																		#DIV/0!			
TUH	139	1		1						0						N	FLT3-TKD ; NPM1 ; TET2 ; DNMT3A ; CEBPA ; NRAS ; STAG2	k = N ; m = FLT3-ITD ; NPM1	2	2				AML with recurrent genetic abnormalities		4															0								CTI						0											#DIV/0!														1	y			High			HE	Yes	High	n																		#DIV/0!			
TUH	140	1	70	2		??/09/2013				1	#VALUE!	1	#VALUE!	1	1	cmplx and monosomal karyotype	TP53	k = cmplx and monosomal : m = TP53	3	3				AML with mutated TP53 or AML with myelodysplasia-related cytogenetic abnormalities (AL with complex karyotype)		2	6.6	50	17.9	21.3	34	6929	nd	5.7	nd	nd	nd	nd	12.9	nd	nd	60	9.2	2.34	nd	nd	2.25	1161	VDZ	01/06/11	0		1	05/05/11	1	01/18/14	nd	nd	nd	nd	nd	nd	nd	94	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd		y			High			HE	Yes	High	n																		#DIV/0!			
TUH	141	2		1						0						46,XX<20>	nd			2						1															0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	142	1	64.7150684931507	1	01/08/20				345	1	345	1	305	1	2	tri8+del7	nd	k = tri8 del7 ; m = nd	3	3	3	EB		AML with myelodysplasia-related cytogenetic abnormalities (del7)	Progressed from MDS/MPN (SMD/SMP sans marqueur g??notypique) ??	5	9.1	35	88.31	21	38	100.2	nd	nd	nd	nd	40	4.06	23.3	nd	nd	259	6.3	2.9	nd	nd	2.79	845	CTI		1	?	1	02/17/20	1	12/18/20	15 PA	occasionally	yes : responsable de proc??d??s chez Motorola, expos?? aux acides chlorydriques, sulfuriques et fluorhydriques	no	no	no	no	92	nd	29.7	no	no	no	no	no	yes	SMD/SMP sans marqueur g??notypique	yes	thrombopathie acquise avec d??faut d'activation de la voie P2Y12 probablement d'origine auto-immune	no	no	no	no	3	n			High	Low			No		n	49	3.67516444	83.7071267	34.7453191	21.4738446	23.8127986	14.86	20.96	3.29744279946164	2.33778625954198	5.63305024899058	3.993660625	Yes			68076.007	1168985.68	17.1717721340501	22	113096	1275
TUH	143	1	64.3315068493151	1	08/24/20				623	0	623	0	797	0	0	N	nd	k = N ; m = nd		2	2	MP1				2	7	78	39.17	71	72										0								CTI		1	07/23/20	1	03/03/20	0	05/09/22										#DIV/0!															n							No		n																		#DIV/0!			
TUH	144	1	48.158904109589	1	01/13/20	09/21/20		252	840	0	252	1	214	1	1	N	nd	k = N ; m = NPM1 ; DNMT3A ; FLT3-TKD ; MECOM ; NRAS ; SNC3 ; SRSF2 ; TET2	1 or 3	2	2	MP3		AML with recurrent genetic abnormalities (AML with mutated NPM1)or AML with myelodysplasia-related gene mutations (AML with mutated SRSF2)		5	10.8	107	21.8	2	76	827	nd	nd	nd	nd	20	< 0,468	6.1	nd	nd	106	5	3.25	nd	nd	1.31	252	CTI		1	?	1	02/20/20	0	05/02/22	no	no	ing??nieur chez orange	no	no	no	no	77.5	1.8	23.9197530864198	no	no	no	no	no	no	no	no	no	no	no	no	no	3	n			Low	Low			No		n	21	2.81423967	35.9612445	15.2948317	10.384195	7.46797817	7.91	11.73	2.65486725663717	1.79028132992327	4.54630145385588	3.06574974424552	Yes					#DIV/0!			2629
TUH	145	1	44.1150684931507	1	01/23/20				872	0	872	0	847	0	0	N	nd	k = N ; m = nd		2	2	MP3				5	10.4	110	92.66	37	40										0								CTI				1	02/17/20	0	06/13/22										#DIV/0!															n							No		y																		#DIV/0!			
TUH	146	2	62.854794520548	1	08/25/20				678	0	678	0	823	0	0	N	nd	k = N ; m = FLT3-ITD ; DNMT3A ; NPM1 ; IDH2	2	0	2	CMP		AML with recurrent genetic abnormalities (AML with mutated NPM1)		4	7.5	79	104.98	51	63								13	nd	nd	85	10.4	3.1	nd	nd	1.24	985	CTI		1	07/27/20	1	04/02/20	0	07/04/22	no	no	Fromag??re au centre commercial leclerc	no	immunoth??rapie pour K du sein	Yes, radioth??rapie pour K du sein	no	80	1.65	29,4 (mais apr??s chirurgie bariatrique pour ob??sit??)	yes	DT2	no	yes	no	yes	K du sein	no	no	no	no	no	no		n							No		n																266956	200100	0.749561725527802	10	13198	2701
TUH	147	1	63.1616438356164	1	04/24/20				433	0	433	0	392	0	0	N	nd	k = N ; m = nd		2	2	MP2				0	8.1	189	244.98	96	95										0								CTI	29/04/2020	1	10/14/20	1	06/04/20	0	07/01/21										#DIV/0!															n							No		n																		#DIV/0!			
TUH	148	2	69.7287671232877	1	05/12/20				270	1	202	1				inv(3) del5 del7	nd	k = inv3 del5 del7 ; m = nd	3	3	3	MPP		AML with myelodysplasia-related cytogenetic abnormalities (del5+del7)	Therapy-related	2ndR_Cancer	8.3	38	117.89	94	93										0								CTI	14/05/2020	0		0	11/30/20	1	02/06/21										#DIV/0!															n							No		n																		#DIV/0!			
TUH	149	2	75.5369863013699	2	05/26/20				173	1	173	1	97	1	2	del12p tri9 tri21	nd	k = del12p tri9 tri21 tri8 ; m = IDH2	2	2	2	CMP		AML with myelodysplasia-related cytogenetic abnormalities (del12p ; tri8)		R	10	183	27.94	11	29								4.5	nd	nd	55	5.9	4.45	nd	nd	1.22	227	VDZ		0		1	08/10/20	1	11/15/20	35 PA	no	nd	no	no	no	no	56	1.61	21.6041047799082	no	no	no	no	no	yes	adenofibrome sein D	no	no	no	no	no	no		n							No		n																39809.169	588296.729	14.7779203579959	34	28594	3960.5
TUH	150	2	59.9561643835616	2	06/03/20	11/07/20		157	226	1	157	1	51	1	1	t(1;1ou10ou15)	nd	k = translocation d??s??qulibr??edu chromosome 1,10,15 ; del1p ; m = NPM1 isol??e	1	2	2	MP3		AML with recurrent genetic abnormalities (AML with mutated NPM1)		R	10.9	23	74.24	38	63								21	5	16	48	5.5	2.51	nd	nd	3.35	362	CTI		0		1	09/17/20	1	01/15/21	yes, undetailed	no	clerc de notaire	no	no	no	no	60.6	1.63	22.8085362640671	no	no	no	yes	no	no	no	yes	scl??rose en plaques ; dysimmunit?? avec thrombop??nie immunologique (anticorps anti-plaquettes positifs) ; l??g??re monocytose chronique	no	no	no	no		n							No		n																50358.027	573399.049	11.3864478646076	31	8223	757
TUH	151	2	79.7178082191781	1	06/11/20	01/22/21		225	491	0	225	1	197	1	1	N	nd	k = N ; m = nd		2	2	MP2				5	7	220	303.12	84	88										0								VDZ				1	07/09/20	0	10/15/21										#DIV/0!															n							No		n																		#DIV/0!			
TUH	152	1	69.4082191780822	1	06/03/20				98	0	98	1				tri8 tri13	nd	k = tri8 tri13 ; m = FLT3-TKD	2	2	2	CMP		AML with myelodysplasia-related cytogenetic abnormalities (tri8)	Progressed from MDS/MPN (secondaire ?  LMMC1 puis 2)	2ndR_SMP	8	17	40.86	9.6	33								5	nd	nd	174	11.2	2.6	nd	nd	1.96	3694	Autre				0	09/09/20	0	09/09/20	40 PA	no	employ?? de France Telecom	no	vidaza dans le cadre de la LMMC2	no	no	130	nd	36	yes	DT2	no	yes	no	yes	LMMC2 trait??e par VIDAZA et hydrea	no	no	no	no	no	no		n							No		n																66832.561	765740.163	11.4575912031861	14	26052	
TUH	153	2	66.7342465753425	1	06/30/20				658	0	658	0	617	0	0	t(15;17) del17p tri8q	nd	k = t(15;17) del17p tri8q ; m = nd	1	0	1	GP		AML with recurrent genetic abnormalities (APL with t(15;17))		3	6.3	5	4.12	74	93								11	nd	nd	153	7	5.5	nd	nd	2.42	257	Atra				1	08/10/20	0	04/19/22	no	no	charg??e de communication et de pr??vention ?  la CPAM	no	no	no	no	81	1.62	30.8641975308642	no	no	no	yes	yes	yes	m??lanome dorsal et sein	no	no	no	no	no	no		n							No		n																6694.724	381714.208	57.0171687436256	5	40323.48	
TUH	154	2	81.6602739726027	1	07/07/20				112	1	112	1				N	nd	k = N ; m = FLT3-ITD ; DNMT3A ; NPM1	2	0	2	MP2		AML with recurrent genetic abnormalities (AML with mutated NPM1)		4	10.7	59	232.18	90.1	84								18.7	11.2	7.5	143	9.2	3.26	nd	nd	1.51	3014	VDZ		0		0	ND	1	10/27/20	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd		n							No		n																7638.487	24580.534	3.21798466109846	5	12404	
TUH	155	2	65.1671232876712	1	07/16/20				97	1	35	1				Cx	nd	k = cmplx ; m = TED2 ; CBL	3	0	2	EB		AML with myelodysplasia-related cytogenetic abnormalities (cmplx karyotype)	Progressed from MDS/MPN (secondaire ?  LMCC0 puis 2)	2ndR_SMP	9.4	21	303.25	64	35								7	nd	nd	164	4.8	2.9	nd	nd	1.56	161	CTI		0		0	08/20/20	1	10/21/20	no	no	comptable	no	vidaza dans le cadre de la LMMC	no	no	60	1.73	20.0474456213038	no	no	no	no	no	yes	LMMC0 qui a ??volu?? en LMCC2	no	no	no	no	no	no		n							No		n																7990.727	39629.877	4.95948328606396	14	26824.757	
TUH	156	2	76.9041095890411	1	06/23/20				91	1	91	1				t(X;1) t(8;20)	nd	k = t(X;1) t(8;20) ; m = CEBPA	1	0	2	GMP		AML with recurrent genetic abnormalities (AML wth in-frame bZIP mutated CEBPA)	Progressed from MDS	2ndR_MDS	7.7	8	15.14	24	29								12	nd	nd	49	5.8	3.8	nd	nd	2.12	846	VDZ		0		0	ND	1	09/22/20	no	no	secr??taire dans l'??ducation nationale	no	no	no	no	63	1.55	26.2226847034339	no	no	no	no	no	yes	nodule sein D ; SMD-MLD	no	no	yes	no	no	no		n							No		n																10737.578	31488.81	2.93258032677388	16	17797.936	
TUH	157	2	25.5342465753425	1	08/09/20				32	0	32	0	0	0	0	t(15;17) del9q	nd	k = t(15;17) del9q ; m = nd	1	0	1	GP		AML with recurrent genetic abnormalities (APL with t(15;17))		3	11.7	23	11	29	75										0								Atra				1	09/10/20	0	09/10/20										#DIV/0!															n							No		n																		#DIV/0!			
TUH	158	1	74.4602739726027	1	08/27/20	12/09/20		104	105	1	104	1	44	1	1	tri8	nd	k = tri8 ; m = nd 		0	2	MP3				5	4.1	167	79.66	11	71										0								VDZ		0		1	10/26/20	1	12/10/20										#DIV/0!															n							No		n																		#DIV/0!			
TUH	159							0		0							nd			0																					0														0											#DIV/0!															n							No		n																		#DIV/0!			
TUH	160	1	66.9095890410959	1	09/07/20				34	1	34	1				del12p tri8 t(11;11)	nd	k = del12p tri8 t(11;11) ; m = JAK2 ; ASXL1 ; NPM1	3	0	2	MPP		AML with myelodysplasia-related cytogenetic abnormalities (del12p) or AML with myelodysplasia-related gene mutations (AML wth mutated ASXL1) or AML with recurrent genetic abnormalities (AML with mutated NPM1)	Progressed from MDS/MPN (polyglobulie de Vaquez JAK2 V617F)	2ndR_SMP	11.6	54	135.88	64	61	165	nd	nd	nd	nd	nd	nd	13	nd	nd	190	7.7	1.7	nd	nd	1.41	1275	VDZ		0		0	ND	1	10/11/20	80 PA	no	entra??neur de chevaux de course	no	no	no	no	105	nd	> 30	yes	DT2 (extremely severe)	no	yes	yes	yes	SMP : polyglobulie de Vaquez JAK2 V617F	yes	neuropathie diab??tique ; r??tinopathie diab??tique ; n??phropathie diab??tique avec maladie r??nale chronique de stade III	no	no	no	no		n				Low			No		n	164.12	106.42	183.94	19.81	18.01	39.69	14.59	19.49	11.2488005483208	8.42072857875834	12.6072652501714	9.4376603386352						#DIV/0!			
TUH	161	1	46.1616438356164	1	09/29/20				619	0	619	0	582	0	0	N	nd	k = N ; m = SMC1A ; DNMT3A ; NPM1 ; (KRAS ; NRAS ; PTPN1 ; FLT3 mais en proportions minimes, d??tect??es au NGS)	1	0	2	MP2		AML with recurrent genetic abnormalities (AML with mutated NPM1)		4	8.9	26	73.23	44	69	1352	nd	nd	nd	nd	29	nd	6	nd	nd	80	5	3.8	nd	nd	1.38	272	CTI				1	11/05/20	0	06/10/22	yes, undetailed	no	nd	no	no	no	no	170	1.74	56.1500858766019	no	no	no	no	no	no	no	no	no	no	no	no	no	4	n				High			No		y	42.96	28.66	139.9	96.93	7.97	6.32	9.07	20.16	4.73649393605292	2.13095238095238	15.4244762954796	6.93948412698413				110881.64	603429.305	5.44210299378689	7	14981	
TUH	162	2	63.9835616438356	1	11/24/20	02/25/21		93	433	1	93	1	58	1	1	N	nd	k = N ; m = DNMT3A ; FLT3-TKD ; IDH1 ; NPM1 ; FLT3-ITD	2	0	2	GP		AML with recurrent genetic abnormalities (AML with mutated NPM1)		1	9.9	34	192.93	96	96	726	nd	nd	nd	nd	9	7.46	7.8	nd	nd	56	9.1	3.39	nd	nd	1.14	640	CTI	11/27/20	0		1	12/29/20	1	01/31/22	no	no	nd	no	no	no	no	111	1.67	39.8006382444691	no	no	no	nd	no	no	no	no	no	no	no	no	no	3	n			Low	Low		HE	Yes	Low	y	13.56	7.03	74.37	60.81	5.26	1.27	1.88	6.08	7.21276595744681	2.23026315789474	39.5585106382979	12.2319078947368				107070.584	285715.427	2.66847733827622	8	6575.7	
TUH	163	2	60.1260273972603	1	11/24/20				622	0	622	0	567	0	0	tri8	nd	k = tri8 ; m = ASXL1	3	0	2	CMP		AML with myelodysplasia-related gene mutations (AML with utated ASXL1)	Progressed from MDS/MPN (LMMC ?)	4	8.7	5	66.97	4	28	2451.9	nd	nd	nd	nd	14	0.62	13	nd	nd	73	4.6	1.4	nd	nd	2.18	364	CTI		1	05/26/21	1	01/18/21	0	08/08/22	25 PA	no	assistante juridique puis auxiliaire de scolarit?? pour enfant handicap?? dans une ??cole	no	no	no	no	63	1.58	25.2363403300753	no	no	no	no	no	yes	SMD JAK2 V617F (LMMC ??)	no	no	no	no	no	no	3	n			Low	Low			No		y	35.38	25.47	99.01	63.62	6.58	3.33	12.68	13.97	2.79022082018927	2.53256979241231	7.80835962145111	7.0873299928418						#DIV/0!			
TUH	164	2	50.4575342465753	1	12/01/20	07/01/21			477	1	212	1	128	1	1	N	nd	k = N ; m = ATM ; NRAS	2	0	2	MPP		AML not otherwise specified		4	10.9	70	76.17	20	49	1600	nd	nd	nd	nd	31	1.82	6.6	nd	nd	93	7.9	3.5	nd	nd	0.59	1316	CTI		1	05/06/21	1	02/23/21	1	03/23/22	half a package every day, since ??? ? 	no	banquier	no	no	no	no	69	1.78	21.7775533392248	no	no	no	no	no	no	no	no	no	no	no	no	no	3	n			High	High			No		n	31.47	25.4	124.02	92.54	0.98	5.09	7.79	14.81	4.0397946084724	2.12491559756921	15.9204107830552	8.37407157326131	Yes					#DIV/0!			
TUH	165	1	78.0739726027397	1	12/07/20				6	1	6	1				tri8	nd	k = tri8 ; m = DNMT3A	2	0	2	MPP		AML with myelodysplasia-related cytogenetic abnormalities (tri8)	Progressed from MDS	2ndR_MDS	12.5	19	100.15	14	51	441.7	nd	nd	nd	nd	nd	nd	12	nd	nd	141	4.7	3.4	nd	nd	1.04	833	BSC		0		0	ND	1	12/13/20	yes, undetailed	2 to 3 glasses of wine everyday	service informatique de la d??p??che	no	no	no	no	76.4	1.78	24.1131170306779	no	no	no	yes	yes	no	no	yes	AOMI ; potentiel syndrome dysm??tabolique	no	no	no	no	3	n			Low	Low			No		y	65.95	48.77	122.22	56.27	9.81	7.36	13.59	12.83	4.85283296541575	5.14029618082619	8.99337748344371	9.52611067809821	Yes			58159.745	1106460.673	19.0245103894455	9	60940.344	
TUH	166	1	43.6	1	12/09/20				299	0	299	0	273	0	0	t(9;11)	nd	k = t(9;11) ; m = NRAS	2	0	2	MP3		AML with recurrent genetic abnormalities(AML with t(9;11))		5	11.4	50	246.67	97	94	3512	nd	nd	nd	nd	18	20.5	108.9	107.9	1	84	6.1	2.33	nd	nd	0.76	1579	CTI				1	01/04/21	0	10/04/21	no	no	dans le batiment	no	no	no	no	63.2	1.75	20.6367346938775	no	no	no	no	yes	no	no	no	no	no	no	no	no	4	n				High			No		n	85.66	44.88	214.67	129.01	22.08	18.69	21.22	24.48	4.03675777568332	3.49918300653595	10.1163996229972	8.76919934640523						#DIV/0!			
TUH	167	2	67.4630136986301	1	12/11/20				28	1	28	1				Mono Cx	nd	k = monosomal ; m = TP53 ; IDH2	3	0	3	CMP		AML with mutated TP53		1	7.1	60	73.52	85	68	1633	nd	nd	nd	nd	1.93	26	9.5	nd	nd	133	4.8	3.92	nd	nd	2.09	483	CTI		0		0	ND	1	01/08/21	yes, undetailed	no	nd	no	no	no	no	62	1.5	27.5555555555556	no	no	no	yes	no	yes	carcinome collo??de ? Fibroad??nome intracanaliculaire sein D ? ; fibromatose ut??rin ; micronodules lobe moyen poumon	yes	asthme	no	no	no	no	3	n			Low	Low			No		y	16.09	5.43	30.05	13.97	7.75	2.91	4.75	7.25	3.38736842105263	2.21931034482759	6.32631578947369	4.1448275862069				233314.156	309160.183	1.32508111938137	32	23572	
TUH	168	1	56.5260273972603	1	12/17/20				581	0	581	0	542	0	0	t(11;17) delY	nd	k = t(11;17) delY ; m = 0	2	0	2	GP		AML with recurrent genetic abnormalities (APL with other RARA rearrangements = APL with t(11;17)))		2	7.7	46	25.47	37	54	2579.9	nd	nd	nd	nd	nd	nd	8	nd	nd	60	5.3	5.7	nd	nd	9.64	575	CTI		1	05/27/21	1	01/25/21	0	07/21/22	10 PA	no	cadre chez airbus	no	no	no	no	69	1.72	23.3234180638183	no	no	no	no	no	no	no	no	no	no	no	no	no	3	n			High	Low			To do		y	27.35	16.92	82.84	55.49	6.92	3.52	10.01	14.19	2.73226773226773	1.92741367159972	8.27572427572428	5.83791402396054				55939.895	1059733.871	18.9441519509466	17	21709	
TUH	169	1	56.6109589041096	1	01/05/21				371	0	371	0	295	0	0	N	nd	k = N ; m = FLT3-ITD ; IDH1 ; NPM1	2	0	2	GP		AML with recurrent genetic abnormalities (AML with mutated NPM1)		1	12.9	34	28.33	88	90	306	nd	nd	nd	nd	33	2.97	4	nd	nd	93	6.5	4.5	nd	nd	1.49	560	VDZ				1	03/22/21	0	01/11/22	no	no	inspecteur qualit?? ?  airbus	no	no	no	no	86	1.76	27.7634297520661	no	no	no	yes	no	no	no	no	no	no	no	no	no	3	n			High	Low			No		n	24.32	12.57	36.67	12.35	8.61	3.14	2.8	5.42	8.68571428571429	4.48708487084871	13.0964285714286	6.76568265682657	Yes			71020.108	192638.818	2.71245459102935	11	6582	
TUH	170	1	38.7369863013699	1	01/09/21				422	0	422	0	384	0	0	inv(16)	nd	k = inv16 ; m = KIT ; NRAS ; CBFB-MYH11	1	0	1	GMP		AML with recurrent genetic abnormalities (AML with inv(16))		5	7.1	40	112.4	88	72	1464	nd	nd	nd	nd	34	nd	3	nd	nd	71	6.6	3.1	nd	nd	1.54	2466	CTI	01/14/21			1	02/16/21	0	03/07/22	10 g of rolled tobacco every day, since ??? ?	no	nd	no	no	no	no	88	1.85	25.7121986851717	no	no	no	no	no	no	no	yes	accident isch??mique c??r??bral transitoire	no	no	no	no	3	n			Low	High			No		y	28.66	19.1	109.93	81.26	8.16	1.41	7.03	10.84	4.07681365576102	2.64391143911439	15.6372688477952	10.1411439114391	Yes			45341.174	103840.916	2.29021233548121	20	5508	
TUH	171	1	58.7671232876712	1	01/10/21	07/27/21			252	1	198	1	161	1	1	N	nd	k = N ; m = DNMT3A ; NPM1 ; FLT3-ITD	2	0	2	GP		AML with recurrent genetic abnormalities (AML wth mutated NPM1)		1	16.4	73	83.64	95	92	609	nd	nd	nd	nd	30	3.94	4	nd	nd	71	6.5	8	nd	nd	1.82	834	CTI		0		1	02/16/21	1	09/19/21	no	no	militaire puis employ?? chez airbus	no	no	no	no	68	1.71	23.2550186382135	no	no	yes	no	no	no	no	yes	cardiopathie ish??mique	no	no	no	no	3	n			Low	High			No		y	18.93	10.57	151.16	132.23	6.11	2.26	3.13	10.41	6.04792332268371	1.81844380403458	48.2939297124601	14.5206532180596	Yes			42565.642	99705.63	2.34239695010356	15	3840	
TUH	172	1	28.8876712328767	1	01/15/21				553	0	553	0	514	0	0	t(8;21)	nd	k = t(8;21) ; m = nd	1	0	1	GMP				2	5.6	14	33.9	57	50										0								CTI				1	02/23/21	0	07/22/22										#DIV/0!															n							No		y																		#DIV/0!			
TUH	173	1	82.813698630137	2	03/11/21				19	1	19	1				tri1q delY	nd	k = tri1q delY ; m = nd		0	2	GP				R	10.8	27			82										0								Autre		0		0	ND	1	03/30/21										#DIV/0!															n							No		y																		#DIV/0!			
TUH	174	1	82.1041095890411	1	03/29/21	12/13/21			465	0	259	1	159	1	1	t(X;6)	nd	k = t(X;6) ; m = nd		0	2	CMP				2	11.2	221	0.9	na	50										0								VDZ				1	07/07/21	0	07/07/22										#DIV/0!															n							No																				#DIV/0!			
TUH	175	1	81.386301369863	2	04/14/21				81	1	72	1					nd			0		MPP				E															0								Autre		0		0	06/25/21	1	07/04/21										#DIV/0!															n							No																				#DIV/0!			
TUH	176	1	74.7479452054795	1	04/20/21	08/27/21			396	1	129	1	81	1	1	N	nd	k = N ; m = nd		0	2	MP3			Progressed from MDS	2ndR_MDS	11.2	122	83	47											0								CTI		0		1	06/07/21	1	05/21/22										#DIV/0!															n							No																				#DIV/0!			
TUH	177	1	50.427397260274	1	04/08/21				406	0	406	0	346	0	0	N	nd	k = N ; m = nd		0	2	MP2				5															0								CTI				1	06/07/21	0	05/19/22										#DIV/0!															n							No																				#DIV/0!			
TUH	178	2	55.0958904109589	1	04/20/21				357	0	357	0	315	0	0	N	nd	k = N ; m = DNMT3A ; CEBPA ; NPM1 ; KIT ; RAD21	1	0	2	MP2		AML with recurrent genetic abnormalities (AML with mutated NPM1)		2	9	80	41.55	76	70	318.2	nd	nd	nd	nd	20	0.82	4	nd	nd	70	5.2	5	nd	nd	1.21	942	CTI				1	06/01/21	0	04/12/22	50 PA	no	"cultive des fraises et des asperges et est au contact d'animaux (cheval, ??ne, ch??vres) chez ""par cet jardin"""	no	no	no	no	66	1.6	25.78125	no	no	no	no	no	no	no	no	no	no	no	no	no	3	n			High				No															Yes					#DIV/0!			605
TUH	179	1	55	1	05/04/21				36	1	36	1				N	FLT3-ITD ; DNMT3A	k = N ; m = FLT3-ITD ; DNMT3A	2	0	2	MPP		AML not otherwise specified		1	4.9	76	354.85	na	94	1903.2	nd	nd	nd	nd	nd	nd	4	nd	nd	71	10.4	3.8	nd	nd	2.51	3612	CTI		0		0	ND	1	06/09/21	30 PA	no	peintre en batiment	no	no	no	no	64.8	1.8	20	no	no	no	yes	no	no	no	no	no	no	no	no	no	3				High				No															Yes					#DIV/0!			2198
TUH	180	2	74	1	05/21/21				433	0	433	0	393	0	0	N	FLT3-ITD ; NPM1	k = N ; m = NPM1 ; FLT3-ITD	2	0	2	GP		AML with recurrent genetic abormalities (AML with mutated NPM1)		1	6.2	169	58.81	84	89	1407	nd	nd	nd	nd	34	3.02	5.5	nd	nd	93	6.6	3.77	nd	nd	1.38	352	CTI				1	06/30/21	0	07/28/22	no	no	d??lainage ?  Mazamet	no	no	no	no	52.7	1.58	21.1103989745233	no	no	no	no	no	no	no	no	no	no	no	no	no	3				Low	Low			No			27	6.33547056	45.3260493	18.4884132	10.682684	9.81948156	6.99	12.74	3.86266094420601	2.1193092621664	6.48441334763949	3.55777467032967	Yes					#DIV/0!			273
TUH	181	1	53	1	05/25/21	06/21/22			428	0	392	1	350	1	1	inv(16) del7q	0	k = inv16 del7q ; m = KIT	1 or 3 ??	0	1	GMP		AML with recurrent genetic abnormalities (AML with inv16) or AML with myelodysplasia-related cytogenetic abnormalities (unbalanced clonal abnormalitie : del7q)		4	8.7	16	17.55	na	53	230	nd	nd	nd	nd	26	nd	6.4	nd	nd	136	4.8	1.93	nd	nd	1.23	546	CTI				1	07/06/21	0	07/27/22	yes, undetailed	no	ost??opathe	no	no	no	no	82	1.79	25.5922099809619	no	no	no	no	no	no	no	no	no	no	no	no	no	3				High	High			No			82	13.5600436	196.146918	113.864334	19.7336238	48.9889159	21.89	27.25	3.74600274097761	3.00917431192661	8.96057185929648	7.19805203669725	Yes					#DIV/0!			367
TUH	182	1	75	1	05/28/21				174	0	174	1				N	FLT3-ITD ; NPM1			0	2	MP2				2	9.8	47	101.04	72	78										0								VDZ				0	ND	0	11/18/21										#DIV/0!																						No																				#DIV/0!			
TUH	183	1	47	1	06/18/21	04/07/22			349	0	293	1	247	1	1	tri20 ins(9;4ou8)	DNMT3A			0	2	GPMP				2	4.3	42	181.4	66	84										0								CTI		1	11/17/21	1	08/03/21	0	06/02/22										#DIV/0!																						No																				#DIV/0!			
TUH	184	1	59	1	06/22/21				65	1	49	1				tetra11q tri8	ASXL1			0	2	MP3				2ndR_SMP	7.6	72	154.45	26	58										0								VDZ		0		0	08/10/21	1	08/26/21										#DIV/0!																						No																				#DIV/0!			
TUH	185	1	73	2	06/23/21				67	1	67	1				N	FLT3-ITD ; ASXL1			0	2	MPP				R	14.6	88	10.79	47	65										0								BSC		0		0	ND	1	08/29/21										#DIV/0!																						No																				#DIV/0!			2476.5
TUH	186	1	46		07/06/21				142	0	142	0	107	0	0	t(8;21)	FLT3-ITD	k = t(8;21) ; m = FLT3-ITD ; KIT ; DHX15	1	0	1	GMP		AML with recurrent genetic abnormalities (AML with t(8;21))		1	8.6	47	35.41	84	70	1809	nd	nd	nd	nd	24	nd	12.4	nd	nd	92	8.5	4.95	nd	nd	3.13	2150	CTI				1	08/10/21	0	11/25/21	20 PA	no	magasinier cariste chez point P	no	no	no	no	79.8	1.66	28.9592103353172	no	no	no	yes	no	no	no	no	no	no	no	no	no	4					Low			No			34	4.20796722	89.7690337	55.960515	13.4527139	16.1478376	5.59	19.04	6.08228980322004	1.78571428571429	16.0588611270125	4.71476017331933	Yes					#DIV/0!			
TUH	187	1	53		07/08/21				362	0	362	0	322	0	0	N	FLT3-ITD ; NPM1 ; DNMT3A			0	2	MP2					9.4	42	153.05	81											0								CTI				1	08/17/21	0	07/05/22										#DIV/0!																						No																				#DIV/0!			
TUH	188	2	73		07/09/21	06/23/22			382	0	349	1	317	1	1	N	FLT3-ITD ; NPM1 ; CEBPA			0	2	MP2					8.5	111	167.15	62											0								CTI				1	08/10/21	0	07/26/22										#DIV/0!																						No																				#DIV/0!			
TUH	189	2	52		07/19/21				332	0	332	0	303	0	0	N	NPM1 ; DNMT3A			0	2	MP2																			0								CTI				1	08/17/21	0	06/16/22										#DIV/0!																						No																				#DIV/0!			316
TUH	190	1	76	1	07/21/21				87	1	64	1					0			0		MP3				2ndR_SMP															0								VDZ		0		0	09/23/21	1	10/16/21										#DIV/0!																						No																				#DIV/0!			
TUH	191	2	54	1	08/23/21	01/19/22			211	0	149	1	110	1	1	N	FLT3-ITD ; NPM1 ; DNMT3A			0	2	MP2				5					55										0								CTI				1	10/01/21	0	03/22/22										#DIV/0!																						No																				#DIV/0!			
TUH	192	2	66	1	10/08/21				313	0	313	0	238	0	0	N	FLT3-ITD ; NPM1			0	2	CMP				4	9.1	40	178.85	80	89										0								CTI				1	12/22/21	0	08/17/22										#DIV/0!																						No																				#DIV/0!			
TUH	193	2	76	1	10/13/21				199	0	63	1				tri8	FLT3-TKD ; ASXL1			0	2	CMP				4					30										0								CTI				0	12/15/21	0	04/30/22										#DIV/0!																						No																				#DIV/0!			
TUH	194	2	75	1	11/13/21				262	0	262	0	211	0	0	inv(9)	FLT3-ITD ; NPM1			0	2	MP1				4	5.7	148	96	73	75										0								CTI				1	01/03/22	0	08/02/22										#DIV/0!																						No																				#DIV/0!			999.5
TUH	195	1	62	2	11/22/21				226	0	226	0	147	0	0	Mono Cx	IDH2	k = monosomal complex ; m = IDH2	3	0	3	MPP		AML with myelodysplasia-related cytogenetic abnormalities (cmplx karyotype)		R	8.6	42	114.42	88		673	2.2	21.6	55	39.3			5.2	nd	nd	77	8.1	4.59	nd	nd	2.75	265	Aracytine				1	02/09/22	0	07/06/22	no	no	pompier ; SAMU ; agent immobilier	no	no	no	no	83	1.77	26.4930256312043	no	no	no	no	yes	no	no	no	no	no	no	no	no									No															Yes			25606	32293	1.26114973053191	16147	5690	2609
TUH	196	2	63	1	12/05/21				219	0	219	0	168	0	0	tri21	0	k = tri21 ; m = TP53 ; (ASXL1 ; KRAS ; SMC3 ; TET2 ; TP53 et UDAF1 au NGS ?  des niveaux interm??diaires)	3	0	2	MP3		AML with mutated TP53	Progressed from MDS/MPN (TE)	2ndR_SMP	8.4	51	52.62	79	97	237.5	nd	nd	nd	nd			5	nd	nd	116	6.9	2.9	nd	nd	1.46	698	CTI		1	05/20/22	1	01/25/22	0	07/12/22	no	no	gyn??cologue	no	no	no	no	69	1.63	25.9701155481953	no	no	no	yes	no	yes	thrombocyt??mie essentielle ; masse tumorale apicale ventriculaire G	no	no	no	no	no	no									No															Yes			14307	173313	12.1138603480814	18	24895	3544.5
TUH	197	1	67		12/16/21				1	1	1	1					nd			0		MP3					10.2	140	503.9	96											0								BSC		0		0	ND	1	12/17/21										#DIV/0!																						No															Yes			38375	143447	3.7380325732899	71724	18133	3002
TUH	198	2	68	1	01/10/22				122	0	122	0	83	0	0	N	FLT3-TKD ; CEBPA ; ASXL1	k = N ; m = ASXL1 ; CEBPA ; SRSF2 ; FLT3	3 or 1 ??	0	2	MPP		AML wit myelodysplasia-related gene mutations (ASXL1 ; SRSF2) or AML with in-frame bZIP mutated CEPBA ??	Progressed from MDS (SMD-EB1)	2ndR_MDS	9	94	87.13	28	23	30.7	nd	nd	nd	nd			6	nd	nd	91	7.2	3.7	nd	nd	1.97	234	CTI				1	02/18/22	0	05/12/22	50 PA	occasionally	enqu??trice de sondages	no	no	no	no	94	1.65	34.5270890725436	yes	DT2	no	no	no	yes	SMD-EB1	no	no	no	no	no	no																											27578	18365	0.665929363985786	24	3041	
TUH	199	2	79	1	01/19/22				43	1	43	1				N	NPM1	k = N ; m = NPM1	1	0	2	GP		AML with recurrent genetic abnormalities (AML with mutated NPM1)		1	6.8	12	217.19	93	86	398.4	nd	nd	nd	nd			14	nd	nd	73	7.7	5.2	nd	nd	2.27	788	VDZ				0	ND	1	03/03/22	no	no	nd	no	no	no	no	nd	nd	27.7	yes	DT2	no	yes	no	no	no	no	no	no	no	no	no																											12318	10389	0.843399902581588	5195	596	
TUH	200	1	69	1	01/22/22				172	0	172	0	131	0	0	inv(16)	0	k = t(16;16) (eq inv16) ; m = KRAS ; NRAS ; KIT	1	0	1	CMP		AML with recurrent genetic abnormalities (AML with t(16;16))		4	8.3	18	96.6	22	23	1346.4	nd	nd	nd	nd			20	nd	nd	113	5.3	4.2	nd	nd	2.39	237	CTI				1	03/04/22	0	07/13/22	no	no	agent d'entretien	no	no	no	no	83	1.8	25.6172839506173	no	no	no	no	no	yes	adenoK prostate	no	no	no	no	no	no																											26808	17066	0.636601014622501	237	2855	
TUH	201	1	73	1	02/04/22				151	0	151	0	112	0	0	tri4 + tri6	0	k = tri4 ; tri6 ; m = no	2	0	2	GPMP		AML not otherwise specifed		4	8.9	82	50.95	39	49	1211	nd	nd	nd	nd			9.1	nd	nd	88	5.3	2.83	nd	nd	1.9	437	CTI				1	03/15/22	0	07/05/22	no	no	nd	no	no	no	no	nd	nd	23.1	no	no	no	no	no	yes	adenoK prostatique ; SMD/LMMC en surveillance simple	no	no	no	no	no	no																											13272.87	218224.73	16.4414124450854	129127	40364	
TUH	202	2	72	1	02/05/22				171	0	171	0	123	0	0	N	FLT3-ITD ; NPM1	k = N ; m = FLT3-ITD ; NPM1	2	0	2	MP3		AML with recurrent genetic abnormalities (AML with mutated NPM1)	Progressed from MDS/MPN (TE)	2ndR_SMP	9.5	75	221.84		95	1235	nd	nd	nd	nd			7.2	nd	nd	87	5.9	5.49	nd	nd	2.02	600	CTI				1	03/25/22	0	07/26/22	no	no	cantini??re en restauration scolaire	no	no	no	no	88	1.69	30.8112461048283	no	no	no	no	no	yes	SMP : thrombocyt??mie essentielle JAK2 mut??e trait??e par hydrea et aspegic	no	no	no	no	no	no																											7049.662	3607.58	0.511738009566984	3	1228	
TUH	203	1	75	2	06/17/21	02/09/22			237	0	237	1	190	1	1	N	FLT3-ITD			0	2	CMP				R	15.3	246	4.55	0	10										0								Autre				1	08/03/21	0	02/09/22										#DIV/0!																																										#DIV/0!			
TUH	204	1	75	2	08/27/21				238	0	238	0	151	0	0	N	FLT3-ITD			0	2	CMP				R	10	30	130	82											0								VDZ				1	11/22/21	0	04/22/22										#DIV/0!																																										#DIV/0!			
TUH	205	1	53	2	09/02/20				320	1	118	1				N	FLT3-TKD ; NPM1			0	2	MPP				R	7	21	1.28	0	10										0								Autre		0		0	12/29/20	1	07/19/21										#DIV/0!																																										#DIV/0!			
TUH	206	1	76	2	01/22/21				59	1	59	1				N	FLT3-ITD ; NPM1			0	2	CMP				R	10.4	335	65.82	73	na										0								VDZ		0		0	ND	1	03/22/21										#DIV/0!																																										#DIV/0!			
TUH	207	1	59	2	07/27/21				54	1	54	1				Cx	FLT3-ITD ; NPM1			0	3	GP				R	13.5	106	45.21	na	na										0								VDZ		0		0	ND	1	09/19/21										#DIV/0!																																										#DIV/0!			
TUH	208	2	62	1	02/11/22				146	0	146	0	108	0	0	N	FLT3-ITD ; NPM1 ; DNMT3A	k = N ; m = FLT3-ITD ; DNMT3A ; NPM1 ; (JAK2 ; TET2)	2	0	2	EB		AML with recurrent genetic abnormalities (AML with mutated NPM1)		1	12.6	19	101		95	1127	nd	nd	nd	nd			16.3	6.6	9.7	51	8.1	4.9	nd	nd	1.77	2144	CTI				1	03/21/22	0	07/07/22	no	no	nd	no	no	no	no	81	1.64	30.116002379536	no	no	no	no	no	no	no	no	no	no	no	no	no																											37904.195	56681.27	1.49538250317676	16	1705	
TUH	209	1	75	1	02/17/22				127	0	88	1				N	FLT3-ITD	k = N ; m = FLT3-ITD	2	0	2	CMP		AML not otherwise specifed		4	8.4	31	109.34	65	25	529	nd	nd	nd	nd			9	nd	nd	89	4.6	3.77	nd	nd	1.53	799	CTI				0	05/16/22	0	06/24/22	8 to 20 cigarillos everyday since 16 years old -> 60 PA ?	no	nd	no	no	no	no	73.4	1.8	22.6543209876543	no	no	no	no	no	no	no	yes	polyarthrite rhumato??de	no	no	no	no						High						25	14.7992825	153.721726	128.286387	9.08194167	1.5541145	9.77	23.02	2.55885363357216	1.08601216333623	15.7340558853634	6.67774656820156				6604.184	48580.788	7.35606215695989	21	3148	
TUH	210	2	22	1	02/23/22				132	0	132	0	88	0	0	delX tri8	ASXL1	k = delX tri8 ; m = ASXL1 ; (NRAS ; MGA)	3	0	2	MP3		AML with mtelodysplasia-related cytogenetic abnormalities (tri8) or AML with myelodysplasia-related gene mutations (AML with mutated ASXL1)		5	10.8	155	65	85		276.5	nd	nd	nd	nd			4	nd	nd	78	5.6	3.5	nd	nd	0.92	647	CTI		1	07/28/22	1	04/08/22	0	07/05/22	no	no	??tudiante en comptabilit??	nd	no	no	no	50	1.65	18.3654729109275	no	no	no	no	no	no	no	no	no	no	no	no	no																											69516.034	136201.439	1.95928091927684	24	33640	
TUH	211	2	78		02/24/22				130	0	130	0	57	0	0	N	NPM1 ; DNMT3A	k = N ; m = DNMT3A ; NPM1	1	0	2	MP3		AML with recurrent genetic abnormalities (AML with mutated NPM1) 		4	8.8	144	68.7	70	40	9023	nd	nd	nd	nd			57.5	24.3	33.2	122	9.8	3.6	nd	nd	2.49	3026	VDZ				1	05/08/22	0	07/04/22	no	no	secr??taire de gestion	no	no	no	no	nd	nd	27.7	no	no	no	no	no	no	no	no	no	no	no	no	no																											165039.707	436710.867	2.64609574834013	49	25473	
TUH	212	1	50	1	03/17/22				104	1	52	1				del7 tetra8	NPM1	k = complx (del7 tetra8) ; m = NPM1	3	0	3	MP3		AML with myelodysplasia-related cytogenetic abnormalities (cmplx karyotype) or AML with recurrent genetic abnormalities (AML with mutated NPM1)		5	13	48	72	54	84	1296.7	nd	nd	nd	nd			11	nd	nd	92	6.3	3.7	nd	nd	2.22	961	CTI				0	05/08/22	1	06/29/22	yes, undetailed	yes, undetailed	travaille dans les espaces verts, vit en foyer(sous curatelle pour retard intellectuel)	no	no	no	no	84.5	1.9	23.4072022160665	no	no	no	yes	no	no	no	no	no	no	no	no	no																											72563.817	223519.505	3.08031625458732	15	70519	
TUH	213	2	71	1	04/26/22				34	0	34	0	0	0	0	N	IDH2 ; DNMT3A	k = N ; m = DNMT3A ; IDH2	2	0		MP3		AML not otherwise specifed		5	8.7	29	63.36	80	75	641.2	nd	nd	nd	nd			26	16	10	532	5.6	1.8	nd	nd	0.82	1157	CTI				1	05/30/22	0	05/30/22	no	no	hoteliere	no	no	no	no	nd	nd	33.9	no	no	no	yes	yes	no	no	yes	insuffisance r??nale chronique	no	no	no	no																								Yes			18236.409	77982.288	4.27618661108116	7	4419	
TUH	214	2	71	1	04/27/22				37	0	37	0	0	0	0	t(15;17)	FLT3-ITD	k = t(15;17) ; m = FLT3-ITD	1	0		GP		AML with recurrent genetic abnormalities (APL with t(15;17))		3	10.3	30	143.16	95.3	97	2823	2	18	50	36			14.4	nd	nd	82	5.8	4.98	nd	nd	2.56	845	Atra				1	06/03/22	0	06/03/22	no	no	conductrice de poids lourds	no	no	no	no	67	1.62	25.5296448712087	no	no	no	no	no	no	no	no	no	no	no	no	no																								Yes			18392.622	12274.778	0.667375102908112	7250	10866	
TUH	215	1	72		05/17/22				0	1	0	1				tri4+tri3	IDH1	k = tri3 ; tri4 ; m = IDH1	2	0	2	EB		AML not otherwise specified		0	12.5	48	204.5	97		13739	nd	nd	nd	nd			52.3	47.7	4.59999999999999	262	4.6	2.65	nd	nd	3.38	11291	BSC		0		0	ND	1	05/17/22	no	no	poseur de cloisons dans le batiment	no	no	no	no	nd	nd	24.2	no	no	no	no	no	yes	Suspicion m??ningiome ou lymphome ? 	no	no	no	no	no	no																											26573.175	521412.215	19.621750694074	307074	10706	
TUH	216	2	50	1	05/17/22				49	0	49	0	0	0	0	N	NPM1 ; DNMT3A	k = N ; m = DNMT3A ; NPM1	1	0	2	MP2		AML with recurrent genetic abnormalities (AML with mutated NPM1)	Therapy-related (chemoterapy lymphome B)	2ndR_Cancer	9.8	89	72	60	64	1180	nd	nd	nd	nd	39	2.41	9.4	nd	nd	66	7.3	5.48	nd	nd	1.56	850	CTI				1	07/05/22	0	07/05/22	no	no	assistante logistiquechez Pierre Fabre	no	yes, RCHOP et PL pour lymphome B	no	no	83.1	1.65	30.5234159779614	no	no	no	no	no	yes	Lymphome B	no	no	no	no	no	no	4																										26905.192	443077.884	16.4681182724881	12	1185	
TUH	217	1	74		06/03/22				6	1	6	1					nd			0		GP					10.1	7	180.59	96											0								BSC				0	ND	1	06/09/22										#DIV/0!																																										#DIV/0!			
TUH	218	2	49	1	07/08/22				42	0	42	0	0	0	0	N	FLT3-ITD ; IDH2	k = N ; m = DNMT3A ; IDH2 ; NPM1 ; FLT3-ITD	2	0	2	EB		AML with recurrent genetic abnormalities (AML with mutated NPM1)		1	12.2	41	66.64	70.1	93	613	nd	nd	nd	nd			4	nd	nd	56	5.6	6.1	nd	nd	2.24	729	CTI				1	08/19/22	0	08/19/22	yes, undetailed	no	agent des services hospitaliers ?  l'hopital de gaillac	no	no	no	no	72.9	1.7	25.2249134948097	no	no	no	yes	yes	no	no	yes	AOMI stade 1	no	no	no	no																											15012	29289	1.95103916866507	12	17834	
TUH	219	1	71		07/22/22					0						N	nd	k = N ; m = ASXL1 ; FLT3-ITD ; IDH1	2 or 3 ??	0				AML with myelodysplasia-related gene mutations (ASXL1)		1	4.1	46	164.94	88		775.7	nd	nd	nd	nd			17	nd	nd	107	9	3.5	nd	nd	1.13	1047									no	no	artiste peintre	no	no	no	no	68	1.73	22.7204383708109	no	no	no	no	no	no	no	no	no	no	no	no	no																											82341	45554	0.553235933496071	25	9485	
TUH	BAR								0	0							nd			0																					0																									#DIV/0!																					HE	Yes																				#DIV/0!			
TUH	ROD								0	0							nd			0																					0																									#DIV/0!																					HE	Yes	Low																			#DIV/0!			
UPenn	53			2					0	0							nd			0																					0														0											#DIV/0!															n			Low			HE	Yes	Low																			#DIV/0!			
UPenn	262			ND					0	0							nd			0																					0														0											#DIV/0!															n			High			HE	Yes	Low																			#DIV/0!			
UPenn	325			1					0	0						nd	nd			0						nos															0														0											#DIV/0!														1	n			High			HE	Yes	Low																			#DIV/0!			
UPenn	964								0	0							nd			0																					0																									#DIV/0!																					HE	Yes	Low																			#DIV/0!			
UPenn	973			2					0	0							nd			0																					0														0											#DIV/0!														1	n			High			HE	Yes	Low																			#DIV/0!			
UPenn	1065								0	0						normal	nd			2						5															0														0											#DIV/0!															n						HE	Yes	Low																	154140	750843	4.87117555469054	238		
UPenn	1956			1					0	0							nd			0																					0														0											#DIV/0!															n			High			HE	Yes	Low																			#DIV/0!			
UPenn	5604		68	2												tri8		m = TET2 (vus)											149.3		149.3																		none																																																														
UPenn	6030								0	0							nd			0																					0																									#DIV/0!														3				Low	High		HE	Yes			20	10.1321221	143.023438	122.564777	8.78795807	1.5385808	5.42	15.01	3.690036900369	1.33244503664224	26.3880881918819	9.52854350433045				4167.47	25888.94	6.21214789788529	22		
UPenn	6312								0	0							nd			0																					0																									#DIV/0!														3				High	Low		HE	Yes	High		8	2.43443393	25.1644	17.3887058	5.7990546	0	4.38	7.07	1.82648401826484	1.13154172560113	5.74529680365297	3.55932107496464				11457.82	30550.55	2.66634927062914	nd		
UPenn	6315		58	1					0	0						t(11;19) ; del9	nd	k = t(11;19) del9 ; m = FLT3 (da) ; STAG2 (da) ; NRAS (da)		0									133.5		78.2										0								hydrea																	#DIV/0!														3				High			HE	Yes	High																			#DIV/0!			
UPenn	6369		58	2					0	0						nd	nd	m = STAG2 (da) ; FLT3 (da)		0									220		52.9										0								hydrea																	#DIV/0!														3				High	Low		HE				33	22.7231573	67.3625908	34.8519257	8.71645487	1.07105293	7.35	16.44	4.48979591836735	2.00729927007299	9.16497834013606	4.09748119221411				25593.22	122663.29	4.79280410983847	63		
UPenn	6611		59	2					0	0						tri8 ; t(11;19) ; del9	nd	m = nd		0									107.9		38										0								hydrea																	#DIV/0!														3				High			HE	Yes	Low																	6259.03	131261.28	20.9715051693313	51		
Upenn	6821		80	1												normal		m = TET2 (da) ; NPM1 (da) ; IDH2 (neg) ; IDH1 (neg) ; FLT3 (da) ; ASXL1 (neg)											131.3		87.3																		hydrea																																																														
UPenn	7004		60	1					0	0						tri13	nd	m = RUNX1 (da) ; NPM1 (neg) ; IDH2 (neg) ; IDH1 (neg) ; FLT3 (da)		0									152.5		80.4										0								hydrea																	#DIV/0!														3				High			HE																					#DIV/0!			
UPenn	7031		59	2					0	0						normal	nd	m = NPM1 (da) ; IDH2 (da) ; IDH1 (neg) ; FLT3 (da) ; DNMT3A (da) ; ATM (vus)		0									117		95										0								none																	#DIV/0!														3				High	Low		HE		Low		12	6.88874408	38.8404293	26.4988862	4.75890292	0.69389608	3.13	7.57	3.83386581469649	1.58520475561427	12.4090828434505	5.13083610303831				8774.61	41827.82	4.76691499679188	24		
UPenn	7050		67	1												normal		m = CEBPA (da) ; TET2 (da) ; NPM1 (da) ; IDH2 (neg) ; IDH1 (neg) ; FLT3 (da) ; DNMT3A (da) ; ASXL1 (neg)											191.2		93.4																		hydrea																																																														
UPenn	7090		56	1												normal		m = DICER1 (neg) ; NPM1 (da) ; FLT3 (da) ; DNMT3A (da)											193.4		77.2																		hydrea																																																														
UPenn	7106		73	1					0	0						del19 ; t(1;19) ; del9 ; ??	nd	m = KRAS (da)		0									212.4		96										0								hydrea																	#DIV/0!														3				High			HE																					#DIV/0!			
CANTHER	AML16	1	73	1	10/10/18				646	1	422	1				46, XY	nd	m = FLT3ITD, NPM1, TET2		2						1			238.06	99	98										0								QUANTUM FIRST		0				1	07/17/20										#DIV/0!														yes					High						137	101.02	305.83	168.42	6	12.96	34	86.63	4.02941176470588	1.58143830081958	8.995	3.53030128131132						#DIV/0!			
CANTHER	AML27	2	57	1	02/07/19				364	1	279	1				48, XX	nd	k = t(9;11) ; m = DNMT3A, SMC3, Surexpevi1		2						5b			62.64	32	61										0								3+7		1	08/01/19			1	02/06/20										#DIV/0!														3				High	High						163.047958333333	69.5503889583333	241.0975375	78.0495791666667	69.3131725	24.184396875	77.5016375	81.2613375	2.10380017239421	2.00646412364716	3.11087023806432	2.96694030540661						#DIV/0!			
CANTHER	AML30	1	41	1	01/07/19				1290	0	1290	0				46, XY	nd	m = GATA2, surepevi1		2						4			54.02	57	79										0								CPKC412E2301		1	05/24/19			0											#DIV/0!																			High						113.775191666667	86.7066329166667	224.193025	110.417833333333	8.004518375	19.064040375	17.1	34.9	6.65351998050682	3.2600341451767	13.1107032163743	6.42386891117479						#DIV/0!			
CANTHER	AML31	1	65	1	04/19/19				191	1	61	1				46, XY	nd	k = del(7)(q12q36) ; m = CSF3R, RUNX1, SF3B1, TET2		3						inclassable			102.38	11.8	34										0								Amsa + AraC		0				1	10/27/19										#DIV/0!																			High						110.463709583333	57.5039277083333	209.8040855	99.3403759166667	36.155405375	16.8043765	38.2563855833333	45	2.88745807788642	2.45474910185185	5.48415858688445	4.66231301111111						#DIV/0!			
CANTHER	AML35	1	66	1	03/06/19				1233	0	1233	0				46, XY	nd	k = t(15;17) 		1						3			7.25	50	88										0								ATRA + TrISENOX		0				0											#DIV/0!																			High						65.87828	44.8161	166.009475	100.131195	9.66044875	11.40173125	28.6252175	41.16869	2.30140714214661	1.60020345558724	5.7994135765082	4.03242063325309						#DIV/0!			
CANTHER	AML37	2	85	1	04/03/19				183	1	126	1				Trisomie 8, monosomie 6	nd	m = BCORL1 , CBL, FLT3TKD, IDH1, JAK2, TET2, TP53		3						Inclassable			38.08	70.9											0										0				1	10/03/19										#DIV/0!																			Low						71.0230933333333	40.4015483333333	139.07792	68.0548266666667	15.6976067	14.9239383	13.0857334	23.03	5.42752103854823	3.08393805181647	10.6282098028988	6.03898914459401						#DIV/0!			
CANTHER	AML39	1	71	1	04/13/19				986	1						46, XY	nd	k = inv(16) ; m = KIT, NRAS, CBP-MYH11		1						4			103.59	62	73										0								3+7		0				1	12/24/21										#DIV/0!														3				High	High						45.4267666666667	20.7220456666667	148.10322	102.676453333333	15.0646384	9.6400826	29.399194	35.920642	1.54517047870995	1.26464239326977	5.03766259714467	4.12306717680603						#DIV/0!			
CANTHER	AML44	1	69	1	05/13/19				16	1	16	1					nd	k = t(7;21) ; m = IDH2,Dupm11		3						4			40	91.4	92										0								Amsa + AraC		0				1	05/29/19										#DIV/0!																			Low						64.7204108095238	45.4328625952381	110.494288285714	45.7738774761905	9.85988314285714	9.42766507142857	8.49958961904762	20.21	7.61453360812681	3.20239538889282	12.9999556729299	5.46730768360783						#DIV/0!			
CANTHER	AML45	2	66	1	05/17/19				265	1	27	1				46, XX	nd	m = DNMT3A,  FLT3ITD, IDH2, 		2						Inclassable			160.27	59	26										0								3+7		0				1	02/06/20										#DIV/0!														3				Low	Low						70.3906301333333	43.3165304333333	143.218164	72.8275338666667	10.3533531	16.7207466	15.7084268	19.5775759	4.48107445955908	3.5954722123352	9.11728245122548	7.31541865711781						#DIV/0!			
CANTHER	AML50	2	75	1	09/30/19				314	1	119	1				46, XX	nd	m = DNMT3A, TET2		2						1			10.65	8	85										0										0				1	08/09/20										#DIV/0!														3				Low	High						54.6320735833333	36.9101999583333	169.70202725	115.069953666667	7.809644	9.912229625	18.2355325833333	22.974362875	2.99591324430333	2.37795815625348	9.30611850651963	7.38658252127917						#DIV/0!			
CANTHER	AML58	1	34	1	11/12/19				363	1	20	1					nd			3						Inclassable			280	87	78										0								3+7		0				1	11/09/20										#DIV/0!														3				Low	High						68.8115619333333	49.3979351333333	257.609281	188.797719066667	8.5284127	10.8852141	13.1794524	16.1372735	5.22112450843051	4.26413804868173	19.5462810731044	15.9636186992803						#DIV/0!			
CANTHER	AML64	1	65	1	01/13/20				33	1		1				46, XY	nd	k = t(3;3), t(1;16) ; m = GATA2, SF3B1								2			93.48	47											0										0				1	02/15/20										#DIV/0!														3				Low	High						49.8397286666667	30.9983544166667	141.136917666667	91.297189	9.54197733333333	9.29939691666667	36.7094737777778	40.4397738333333	1.3576802808009	1.23244330871072	3.84470010442112	3.49005210188222						#DIV/0!			
CANTHER	AML65	1	54	1	02/03/20				899	0	899	0				46, XY	nd	m = DNMT3A, IDH2, NPM1		1						1			98.12	96	97										0								3+7		0				0											#DIV/0!														yes					Low						53.5626002222222	39.4398311388889	97.193325	43.6307247777778	4.54799375	9.57477533333333	16.0459258333333	23.13	3.33808100439757	2.31571985396551	6.05719645033467	4.20204604409857						#DIV/0!			
CANTHER	AML72	2	81	1	12/14/20				6	1	6	1				46,XX	nd	m = DNMT3A, FLT3TKD, NPM1, NRAS, PTEN, WT1		2						4			88.19	91.1											0										0				1	12/20/20										#DIV/0!														3				Low	High						80.1999205238095	54.420962452381	204.381218142857	124.181297619048	20.8845058571429	4.89445221428572	16.8021262857143	31.0281705	4.7732006747264	2.58474538561046	12.1640091657107	6.58695678312252						#DIV/0!			
CANTHER	AML41	2	60	1	11/23/18				700	1						46,XX		k = t(1;10)(p35;q11), t(8;12)(p12;q11) ; m = FLT3-TKD		3						4			39	41.4	70																		3+7		0				1	10/23/20																													High						217.058215466667	136.091516066667	897.6705512	680.612335733333	48.06056	32.9061394	58.0950323333333	62.7717187	3.73626120424972	3.45789823764482	15.4517609362779	14.3005571583943									
CANTHER	AML22	2	58	1	11/22/17				1734	0	1734	0				46,XX		m = CSF3R, ETV6, FLT3-ITD, PHF6		2						0			7.78	28.1	61																		QUANTUM FIRST		1	03/20/18			0																														High						183.45	139.57	520.41	336.97	26.13	17.73	33.52	45.94	5.47285202863962	3.99325206791467	15.5253579952267	11.3280365694384									
CANTHER	AML61	1	78	1	12/13/19				232	1	123	1				45, XY		k = t(3;3)(q21;q26) m = NRAS, WT1, surexpevi1		3						2			3.73	21.9	36																		VDZ VEN		0				1	08/01/20																													High						101.1306268	74.1928608	310.4233486	209.2927218	16.1431595	10.7946065	26.3458377333333	46.77	3.83858079684623	2.16229691682703	11.7826334369032	6.63723217019457									
CANTHER	AML68	1	57	1	08/08/17				1808	0	1808	0				47 XY, + 21		m = SRSF2, RUNX1, FLT3-ITD		2						0			13.6	75.2																			3+7		1				0																														High						51.0633343333333	29.5687356666667	281.703577333333	230.640243	7.43969833333333	14.0549003333333	6.79765644444445	23.02	7.51190277865045	2.21821608746018	41.4412790107336	12.2373404575731									
CANTHER	AML71	2	48	1	11/19/20				280	1		1				46, XX		k = t(3,7) ; m = DNMT3A, FLT3-TKD, FLT3-ITD, NPM1		3						2			17	83.4	83																				1	06/24/20			1	08/26/21																													High						107.122674428571	73.469164	290.308865	183.186190571429	24.1592640714286	9.49424635714286	21.0199701904762	61.6	5.09623341317139	1.73900445500928	13.8110978450167	4.71280625									
CANTHER	AML62	2	49	1	12/26/19				937	0	937	0						m = DNMT3A, FLT3-ITD, NPM1, SMC1A											39.08	60	92																		3+7		0				0																														High						102.766974857143	63.7906738571429	274.313930857143	171.546956	22.6909081428571	16.2853928571429	34.3288485238095	53.3	2.99360390098335	1.92808583221656	7.99076993994967	5.14660283034039									
CANTHER	AML56	1	25	1	10/17/19				1008	0	1008	0				46, XY		k = t(8;9) ; m = FLT3-TKD, NPM1, WT1								5			8	5.7	61																		Amsa + AraC		1	03/06/20																																	High						165.696666047619	69.2280244761905	334.044178428571	168.347512380952	81.6863097857143	14.7823317857143	44.71	74.65	3.70603144816862	2.21964723439543	7.47135268236572	4.47480480145441									
CANTHER	AML66	2	46	1	02/10/20				892	0	892	0				46, XX		k = t(8;21) ; m = ASXL1, NRAS, RUNX1-RUNXT1		1						2			5.7	20.3	63																		3+7		0				0																														High						74.71901125	37.695888	222.2056815	147.48667025	30.71165875	6.3114645	32.3775351666667	44.08	2.30774241662857	1.69507738770417	6.8629585407343	5.04096373638838									
CANTHER	AML52	1	60	1	07/09/19				92	1	45	1				47, XY		k = t(1;2) ; m = TP53		3						2			13.46	15	34																		CPKC412E2301		0				1	10/09/19																													High						52.9383522666667	29.7476663666667	197.8535418	144.915189533333	15.3968205	7.7938654	33.2485408	48.06	1.59220077010618	1.10150545706755	5.95074361278436	4.11680278401998									
CANTHER	AML51	1	70	1	07/09/19				464	1		1				47, XY		k = t(1;14) ; m = RUNX1, SRSF2		3						5a			14.53	82	90																				0				1	10/15/20																													High						53.9318124666667	29.8596417666667	195.746012	141.814199533333	14.6059603	9.4662104	23.3670535333333	36.34	2.30802794155166	1.48408950100899	8.37700875383224	5.38651656576775									
CANTHER	AML67	1	74	1	07/10/20				742	0	742	0				46, XY		m = ASXL1, DNMT3A, IDH2, RUNX1		2						0			1.14		30																				0				0																														High						183.870612888889	124.298425222222	308.14471	124.274097111111	34.9797716666667	24.592416	55.8771607777778	95.7	3.29062197022032	1.92132301869267	5.51468087695945	3.21990292580982									
CANTHER	AML38	2	47	1	04/11/19				1197	0	1197	0				46, XX		m = FLT3TKD, IDH1, NPM1, PTPN11		1						2			11.86	59.4	74																		CPKC412A2408		0				0																														High						131.005773333333	81.7971173333334	236.96052	105.954746666667	30.2932275	18.9154285	14.4172136666667	29.04	9.08676089307224	4.51121808999082	16.4359442454449	8.15979752066116									
CANTHER	AML28	1	76	1	10/22/18				352	1		1				46, XY		m = ASXL1, RAD21, RUNX1, SRSF2, TET2		3						Inclassable			3.22	14	62																				0				1	10/09/19																													High						158.870391666667	106.746700416667	259.6143625	100.743970833333	37.6156575	14.50803375	26.5873639166667	39	5.9754096782448	4.07359978632479	9.76457701161028	6.65677852564103									
CANTHER	AML43	1	69	1	05/09/19				52	1	52	1				46, XY		m = ASXL1, BCOR, FLT3TKD, NRAS, SRSF2, TET2, CEBPAsm, CEBPApp1		2						1			18.42	78	82																				0				1	06/30/19																													High						102.781233714286	67.9145179285714	199.273067571429	96.4918338571429	15.7893542857143	19.0773615	16.1886264761905	32	6.34897802265386	3.21191355357143	12.3094487271363	6.22728336160714									
CANTHER	AML55	2	86	1	09/23/19				1032	0	1032	0				44,X,-X		k = del(4)(q21) 		3						4			22.9	37.5																					0				0																														High						51.4649490555556	35.2374651388889	140.52	88.81	8.48947475	8.41	9.71951522222222	16.75	5.29501193000744	3.07253427197347	14.4575111810846	8.38925373134328									
CANTHER	AML63	2	67	1	01/13/20				920	0	920	0				46, XX		m = DNMT3A, IDH2, NPM1, Surexpevi1		2						1			47.4	70	90																		3+7		0				0																														High						54.6804301111111	39.1041367777778	130.049084333333	75.3686542222222	10.7365731666667	4.83972016666667	10.9106168888889	18.9	5.01167172012028	2.89314445032334	11.9194987467457	6.8809039329806									
CANTHER	AML29	2	62	1	01/08/19				57	1	57	1				48, XX		k = t(6;9) ; m = SF3B1		3						5a			3.24	27.3	30																		DEC10 VEN		0				1	03/06/19																													Low						94.2301485833333	71.8710658333333	166.34425525	72.1141066666667	6.525012875	15.834069875	12.66382675	22.65	7.44089053360852	4.16027146063282	13.1353862093857	7.34411722958058									
CANTHER	AML49	1	68	1	05/28/18				405	1	176	1						k =  del(17), t(17;21) ; m = ASXL1, IDH2, PHF6, TP53,		3						0			1.54	22.8	93																				0				1	07/07/19																													Low						54.0133315833333	35.8127112083333	117.065	63.0516684166667	8.4361905	9.764429875	4.75233358333333	13.92	11.3656439802039	3.88026807351533	24.6331613610948	8.40984195402299									
CANTHER	AML54	2	88	1	08/14/19				68	1	21	1				47, XY		k = del(9)(q21), del(17)(p11) ; m = IDH2, TP53,, NRAS, SRSF2, SMC1A		3						5a			14.99	81	95																				0				1	10/21/19																													Low						47.4349806666667	24.9405079166667	110.0754625	62.6404818333333	10.6532640833333	11.8412086666667	28.3921037777778	34.65	1.67071031572495	1.36897491101491	3.87697450536071	3.17678102453102									
CANTHER	AML59	2	76	1	12/05/19				373	1		1				59, XX		k = ; m = JAK2, TP53		NA						Inclassable			2.49	3.3	75																				0				1	12/12/20																													Low						74.0669246666667	59.9337609166667	126.29626025	52.2293355833333	7.847251625	6.285912125	5.68145333333333	18.65	13.0366158658935	3.97141687220733	22.2295692387394	6.77191743967828									
CANTHER	AML48	1	49	1	05/24/19				1154	0	1154	0				46, XY		m = FLT3ITD, IDH2, NPM1		2						1			47.14	87.8	91																		QUANTUM FIRST		1	10/18/19			0																														Low						32.9751211111111	15.2328762777778	64.4095213333333	31.4344002222222	13.363001	4.37924383333333	5.99483433333333	10.58	5.50058922024886	3.1167411258139	10.7441703560004	6.08785645872716									
CANTHER	AML60	2	58	1	12/05/19				803	1		1				46, XY		m = NPM1, TET2		2						Inclassable			37	84	84																		3+7		0				1	02/15/22																													Low						101.98	72.39	120.69	18.71	18.01	11.57	20.12	29.47	5.06858846918489	3.46046827281982	5.99850894632207	4.09535120461486									
CANTHER	AML100	2	30	1	10/07/21				300	0	300	0																																							0																																		Low						19.73	8.26	60.24	40.51	17.86	0.4	12.05	15.28	1.63734439834025	1.29123036649215	4.99917012448133	3.94240837696335									
CANTHER	AML101	1	35	1	10/25/21				9	1	9	1																		73																					0				1	11/03/21																													High						139.3	66	243.15	104.82	34.3	38.97	51.17	67.89	2.72229822161423	2.051848578583	4.75180769982412	3.58152894387981									
CANTHER	AML102	1	86	1	03/30/22				113	0	113	0														5																									0				0																														High						121.3	78.25	307.89	186.59	19.98	23.05	42.09	77.36	2.88191969588976	1.56799379524302	7.31503920171062	3.97996380558428									
CANTHER	AML103	2	47	1	05/20/22				62	0	62	0																		83.9																					0				0																														Low						44	33	62.74	19.15	10.59	2.74	7.33	22.9	6.00272851296044	1.92139737991266	8.5593451568895	2.73973799126638									
CANTHER	AML104	1	29	1	03/05/21				503	0	503	0																		46																					0				0																														High						122	82.8	241.4	119.5	20.5	18.5	29.83	57.9	4.08984244049615	2.10708117443869	8.09252430439155	4.1692573402418									
CANTHER	AML73	2	63	1	12/18/20				26	1	26	1				48, XX	nd	k = t(9;11)(p22;q23), t(9;11)(3'KMT2A+;5'KMT2A+) 		3						5a			109	66	80										0								3+7		0				1	01/13/21										#DIV/0!														3				High	High						149.121782	101.809091125	531.4135245	382.2917425	26.351709375	20.9609815	51.8835943333333	83.882113	2.87416058806463	1.77775423945269	10.2424192334452	6.33524246700843						#DIV/0!			
